The DOI matches its Crossref record; 332 of the 333 references it cites were found in a registry or an index; 220 of the 361 sources its claims cite were checked for support.
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
Open accessAbstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee for Diabetes, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This is the American Diabetes Association's 2026 "Standards of Care" section on cardiovascular disease and risk management in diabetes, providing graded clinical practice recommendations for blood pressure, lipids, antiplatelet therapy, and cardiovascular risk reduction. It synthesizes randomized trial and meta-analytic evidence to recommend individualized blood pressure goals (<130/80 mmHg, with <120 mmHg encouraged in high cardiovascular or kidney risk), statin-based lipid management, and cardioprotective SGLT inhibitors and/or GLP-1 receptor agonists in type 2 diabetes with ASCVD, heart failure, or CKD.
Key findings
- Blood pressure: on-treatment goal is <130/80 mmHg if safely attained, with systolic <120 mmHg encouraged in high cardiovascular or kidney risk. BPROAD (12,821 participants with type 2 diabetes) reduced the primary composite of nonfatal stroke, nonfatal MI, heart failure treatment/hospitalization, or cardiovascular death by 21% (HR 0.79, 95% CI 0.69–0.90) with achieved mean systolic 121.6 vs. 133.2 mmHg; ESPRIT (11,255 participants, 39% with type 2 diabetes) reduced its composite by 12% (HR 0.88, 95% CI 0.78–0.99); SPRINT reduced events by 25% (excluding diabetes); ACCORD BP did not reduce its primary outcome but reduced stroke by 41%.
- Lipids: moderate-intensity statin for ages 40–75 without ASCVD; high-intensity statin for higher-risk primary prevention (LDL-C goal <70 mg/dL) and for all with ASCVD (LDL-C reduction ≥50% and goal <55 mg/dL). A meta-analysis of >18,000 people with diabetes from 14 statin trials showed 9% proportional reduction in all-cause mortality and 13% in vascular mortality per 1 mmol/L (39 mg/dL) LDL-C reduction. Statin-associated diabetes risk was small (meta-analysis of 13 trials, 91,140 participants: OR 1.09; one extra diabetes case per 255 treated for 4 years while preventing 5.4 vascular events).
- Glucose-lowering agents with cardiovascular benefit: three SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) and four GLP-1 RAs (liraglutide, albiglutide, semaglutide, dulaglutide) show significant cardiovascular event reductions; lixisenatide and extended-release exenatide did not. SGLT2 inhibitors reduced heart failure hospitalization (e.g., empagliflozin 35%, canagliflozin 33%, dapagliflozin 17% in respective trials).
- Antiplatelet therapy: aspirin (75–162 mg/day) is recommended for secondary prevention; for primary prevention the benefit is modest and bleeding risk increased (ASCEND: 12% reduction in primary efficacy end point, 8.5% vs. 9.6%, P = 0.01, but major bleeding 3.2% to 4.1%, rate ratio 1.29, P = 0.003).
Methods
This is a clinical practice guideline (ADA Standards of Care in Diabetes—2026, section 10), not a primary research study. Recommendations were developed by the ADA Professional Practice Committee with an evidence-grading system (grades A–E) described in the Introduction and Methodology. The evidence base is a narrative synthesis of randomized controlled trials, meta-analyses, and observational studies on blood pressure, lipid, antiplatelet, and glucose-lowering management in people with diabetes.
Limitations
Stated in the paper: no randomized trials have been specifically designed to assess cardiovascular risk reduction strategies in people with type 1 diabetes, so recommendations for type 1 diabetes are extrapolated from type 2 diabetes data; there is an absence of high-quality data to guide blood pressure goals in type 1 diabetes; very little clinical trial evidence exists for people with type 2 diabetes under age 40 or type 1 diabetes of any age for statin therapy; few older people with diabetes have been enrolled in primary prevention statin trials; and long-term outcome studies are needed to better evaluate the role of MRAs in blood pressure management. Evident from the text: this is a consensus guideline rather than a systematic review with formal meta-analytic pooling of all recommendations, and several recommendations rest on indirect or subgroup evidence (e.g., SPRINT excluded people with diabetes; some statin and PCSK9 evidence in type 1 diabetes comes from small subgroups such as 197 of 27,564 FOURIER participants).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
71 Supported · 67 Partly supported · 62 No full text of the sources · 19 Supported so far · 6 Sources not found · 6 Own interpretation · 5 Couldn’t confirm · 2 Not supported · 1 Mixed support · 1 Not checked yet · 1 No basis given · accuracy not yet measured
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Single-pill antihypertensive combinations may improve medication-taking behavior in some individuals (60,61).”
What the sources say
- Supportedcites [60] Choudhry, 2022, Medication adherence and blood pressure control: a scientific statement from the American Heart Association, Hypertension source
The Interventions to Improve Adherence section reports that patients given polypills containing two antihypertensives were more likely to report taking their blood-pressure medications. It cautions that whether polypills specifically improve adherence remains undetermined; the claim’s tentative wording is consistent with that limitation. No page number is available in our copy. (LLM, conf=0.87)
- Disputedcites [61] Wang, 2023, Efficacy and safety of low-dose triple and quadruple combination pills vs monotherapy, usual care, or placebo for the initial management of hypertension: a systematic review and meta-analysis, JAMA Cardiol sourceExperimental — accuracy not yet measured
The Results (Adverse Effects and Tolerability; page not provided) report similar self-reported treatment adherence with low-dose combination therapy and active comparators, rather than an improvement. The paper does not report an adherence benefit for a subgroup of individuals. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The CAROLINA (Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Type 2 Diabetes) study demonstrated noninferiority between a DPP-4 inhibitor, linagliptin, and a sulfonylurea, glimepiride, on cardiovascular outcomes despite lower rates of hypoglycemia in the linagliptin treatment group (267).”
What the sources say
- Disputedcites [267] Marx, 2015, Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA), Diab Vasc Dis Res sourceExperimental — accuracy not yet measured
The Discussion describes CAROLINA as an ongoing trial designed to test cardiovascular noninferiority, not a trial that had demonstrated it. It attributes the lower incidence of hypoglycaemia with linagliptin to a former study, not to CAROLINA results. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Increasing evidence has demonstrated the benefits of GLP-1 RA or dual GIP/GLP-1 RA on symptoms and outcomes for people with HFpEF and obesity, and while most people with HFpEF have obesity, approximately 45% have diabetes (304,305).”
What the sources say
- Not checked — no full text of the sourcecites [304] Echouffo-Tcheugui, 2016, Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry, Am Heart J source
- Disputedcites [305] Haass, 2011, Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial, Circ Heart Fail sourceExperimental — accuracy not yet measured
The Results, Baseline Characteristics section (page unavailable) reports that 41.3% of the HFpEF patients in the I-PRESERVE cohort had a BMI greater than 30 kg/m²—not most. The paper’s figure of more than 83% combines overweight and obese patients, so it does not support the claim that most had obesity. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Diabetes itself confers independent ASCVD risk, and among people with diabetes, all major cardiovascular risk factors, including hypertension, hyperlipidemia, and obesity, are clustered and common (2).”
What the sources say
- Partly supportedcites [2] Weng, 2019, The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States, Endocrinol Diabetes Metab sourceExperimental — accuracy not yet measured
The Results (Study population and Subgroup analysis by age category; page unavailable) show that hypertension and dyslipidemia were common among patients with type 2 diabetes, and the Discussion reports that 45.2% had ASCVD. The paper does not establish that diabetes independently confers ASCVD risk or report obesity as a common, clustered risk factor. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“diabetes is a risk factor for incident heart failure, which is at least twofold more prevalent in people with diabetes compared with those without diabetes and is a major cause of morbidity and mortality (11).”
What the sources say
- Supportedcites [11] Kodama, 2020, Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis, ESC Heart Fail source
The Results section (‘Overall analysis of new-onset heart failure risk in relation to diabetes mellitus’; page unavailable) reports a pooled risk ratio of 2.14 for new-onset heart failure in people with diabetes compared with those without diabetes. This directly supports diabetes as a risk factor for incident heart failure. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Numerous studies have shown the efficacy of managing individual cardiovascular risk factors in preventing or slowing ASCVD in people with diabetes.”
What the sources say
- Supportedcites [3] Gæde, 2016, Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial, Diabetologia source
The Discussion (page unavailable) says single-risk-factor intervention trials reported risk reductions, although smaller than those in Steno-2, and states that lipid-lowering treatment has proven long-term benefits for CVD reduction. The paper reports these findings as background; its own trial tested multifactorial treatment. (LLM, conf=0.84)
- Supportedcites [4] Gaede, 2008, Effect of a multifactorial intervention on mortality in type 2 diabetes, N Engl J Med source
The opening passage (labeled Abstract in our copy) says trials targeting single risk factors reduced the development and progression of complications in type 2 diabetes. The Discussion specifically reports that antihypertensive and lipid-lowering drugs each reduced cardiovascular-event risk, supporting the claim about managing individual cardiovascular risk factors. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [5] Khunti, 2018, Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: time to overcome multifactorial therapeutic inertia?, Diabetes Obes Metab source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“when all major cardiovascular risk factors are treated to within the target ranges, people with type 2 diabetes have risk of death, MI, or stroke similar to that of the general population (6).”
What the sources say
- Partly supportedcites [6] Rawshani, 2018, Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 7) reports that patients with type 2 diabetes whose five selected risk factors were within target ranges had, at most, marginally higher risks of death, myocardial infarction, and stroke than the general population. But the paper’s limitations (p. 11) say it did not distinguish patients medically treated to reach those ranges from patients already within them without treatment. The comparison is supported; attributing it specifically to treatment is not. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“people with diabetes are at risk for developing structural heart disease and HFrEF in the absence of obstructive coronary artery disease (15).”
What the sources say
- Partly supportedcites [15] Marwick, 2018, Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
The Epidemiology of Diabetes-Associated HF section reports increased heart-failure risk in people with diabetes, and the paper describes structural and functional myocardial abnormalities. It does not specifically establish that people with diabetes develop HFrEF in the absence of obstructive coronary artery disease; the epidemiology section says most published data do not distinguish HFrEF from HFpEF. Page numbers were not available in our copy. (LLM, conf=0.83)
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
What the sources say
- Supportedcites [1] Rawshani, 2017, Mortality and cardiovascular disease in type 1 and type 2 diabetes, N Engl J Med source
The Discussion reports marked reductions in mortality and cardiovascular complications among Swedish adults with both type 1 and type 2 diabetes from 1998 to 2014. It also identifies improved management of cardiovascular risk factors as an important likely contributor, while noting that the observed changes probably reflect several advances. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“People with diabetes may present with a wide spectrum of heart failure, including heart failure with preserved ejection fraction (HFpEF), heart failure with mildly reduced ejection fraction (HFmrEF), or heart failure with reduced ejection fraction (HFrEF) (12,13).”
What the sources say
- Partly supportedcites [12] Maddox, 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
Section 4.9 (page unavailable) says diabetes is common among people with HF and is strongly associated with incident HF. The paper focuses on HFrEF; our copy does not establish that people with diabetes may present across all three listed ejection-fraction categories, particularly HFpEF and HFmrEF. (LLM, conf=0.84)
- Supportedcites [13] Kittleson, 2023, 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction, J Am Coll Cardiol source
Section 7.1 reports that a trial enrolled people with type 2 diabetes and heart failure across the spectrum of left ventricular ejection fraction. Section 3.2 defines that spectrum’s HFrEF, HFmrEF, and HFpEF categories, supporting the claim that people with diabetes may have any of the three. (LLM, conf=0.90)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and is a major cause of morbidity and mortality (11).”
What the sources say
- Partly supportedcites [11] Kodama, 2020, Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis, ESC Heart Fail sourceExperimental — accuracy not yet measured
The Introduction describes heart failure as a major clinical and public-health problem that impairs daily living, and the Results report higher risks of new-onset and recurrent heart failure in people with diabetes. This supports the morbidity aspect. The Methods say the analysis included fatal and nonfatal heart-failure events but excluded studies with only heart-failure mortality as an endpoint; the cited findings do not establish that heart failure is a major cause of mortality in people with diabetes. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“among people with diabetes, all major cardiovascular risk factors, including hypertension, hyperlipidemia, and obesity, are clustered and common (2).”
What the sources say
- Partly supportedcites [2] Weng, 2019, The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States, Endocrinol Diabetes Metab sourceExperimental — accuracy not yet measured
The Results (Study population, Table 1; page unavailable) report that hypertension (79.1%) and dyslipidemia (77.8%) were common in the studied US population with type 2 diabetes. Our copy does not report obesity prevalence or establish that these risk factors cluster in the same individuals, so it does not support the claim about all three factors being clustered and common. (LLM, conf=0.87)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“ASCVD broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
What the sources say
- Partly supportedcites [1] Rawshani, 2017, Mortality and cardiovascular disease in type 1 and type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Outcomes and Mortality sections assess cardiovascular events and cardiovascular deaths in people with diabetes, supporting the claim that cardiovascular disease contributes to morbidity and mortality. The paper does not establish that ASCVD, specifically, is the leading cause of either, and its cardiovascular outcomes include heart failure rather than being limited to ASCVD. Page numbers are unavailable in our copy. (LLM, conf=0.83)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Secondary analyses of ACCORD BP and SPRINT suggest that clinical factors can help identify individuals more likely to benefit from and less likely to be harmed by intensive blood pressure management (49,50).”
What the sources say
- Supportedcites [49] Basu, 2017, Benefit and harm of intensive blood pressure treatment: derivation and validation of risk models using data from the SPRINT and ACCORD trials, PLoS Med source
The Abstract’s Conclusions state that predictive models identified subgroups in both SPRINT and ACCORD-BP with different levels of cardiovascular benefit and serious-adverse-event risk from intensive BP treatment. The Discussion adds that considering multiple factors together helped explain variation in benefit and harm. (LLM, conf=0.93)
- Supportedcites [50] Phillips, 2018, Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension, J Am Coll Cardiol source
The Methods describe a secondary analysis stratifying SPRINT participants by baseline 10-year cardiovascular risk. The Discussion reports that this risk estimate identified groups for whom intensive treatment had more benefit than harm, or the reverse. This source supports the SPRINT portion of the sentence; it does not need to establish the separately cited ACCORD BP analysis. (LLM, conf=0.92)
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Lifestyle intervention, including weight loss in people with overweight or obesity (when appropriate) (22,86), increased physical activity, and medical nutrition therapy, allows some individuals to reduce ASCVD risk factors such as hypertension, dyslipidemia, or obesity.”
What the sources say
- Supportedcites [22] Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation source
Section 4.1 recommends lifestyle programs combining weight loss, dietary changes, and increased physical activity for adults with overweight or obesity. It reports that weight loss achieved through comprehensive lifestyle intervention improves blood pressure and lipid profiles—risk factors named in the claim. Section 4.2 also describes an individualized nutrition plan for adults with type 2 diabetes. (LLM, conf=0.91)
- Supportedcites [86] Virani, 2023, 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines, Circulation source
The guideline’s weight-management Synopsis (page not provided) recommends counseling patients with chronic coronary disease and overweight or obesity to lose weight, especially alongside increased physical activity. Its Synopsis on diabetes also includes lifestyle modification, nutrition, physical activity, and weight management in comprehensive risk-factor control for patients with chronic coronary disease and type 2 diabetes. (LLM, conf=0.90)
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, MRAs reduce albuminuria in people with diabetic nephropathy (83–85).”
What the sources say
- Supportedcites [83] Sato, 2003, Effectiveness of aldosterone blockade in patients with diabetic nephropathy, Hypertension source
The Discussion reports that urinary albumin excretion fell significantly after 24 weeks of spironolactone, a mineralocorticoid receptor antagonist, added to ACE-inhibitor treatment in patients with diabetic nephropathy. The Perspectives table shows a decrease from 389 to 233 mg/g creatinine. The study specifically involved patients with aldosterone escape during ACE-inhibitor therapy. (LLM, conf=0.91)
- Supportedcites [84] Mehdi, 2009, Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy, J Am Soc Nephrol source
The Abstract reports that spironolactone, an MRA, reduced the urine albumin-to-creatinine ratio by 34.0% versus placebo in patients with diabetes, hypertension, and albuminuria who were receiving lisinopril. This supports the cited statement about reducing albuminuria in diabetic nephropathy; the trial tested spironolactone as an addition to ACE inhibition. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [85] Bakris, 2015, Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial, JAMA source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A systematic review of 10 randomized controlled trials reported that compared with control diet, the modified Dietary Approaches to Stop Hypertension (DASH) eating pattern could reduce mean systolic (−3.26 mmHg [95% CI −5.58 to −0.94 mmHg]; P = 0.006) and diastolic (−2.07 mmHg [95% CI −3.68 to −0.46 mmHg]; P = 0.01) blood pressure (54).”
What the sources say
- Supportedcites [54] Guo, 2021, Effects of the modified DASH diet on adults with elevated blood pressure or hypertension: a systematic review and meta-analysis, Front Nutr source
The Results > Effect on BP passage reports that all ten trials measured blood pressure and gives the claimed systolic and diastolic reductions and confidence intervals versus a control diet. The supplied Abstract passage gives the matching P values (0.006 and 0.01). (LLM, conf=0.95)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the use of both ACE inhibitors and ARBs in combination, or the combination of an ACE inhibitor or ARB and a direct renin inhibitor, is contraindicated given the lack of added ASCVD benefit and increased rate of adverse events—namely, hyperkalemia, syncope, and AKI (74–76).”
What the sources say
- Partly supportedcites [74] Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [75] Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med source
- Partly supportedcites [76] Makani, 2013, Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials, BMJ sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“MRAs, including spironolactone and eplerenone, are effective for management of resistant hypertension in people with type 2 diabetes when added to existing treatment with an ACE inhibitor or ARB, thiazide-like diuretic, or dihydropyridine calcium channel blocker (82).”
What the sources say
- Partly supportedcites [82] Williams, 2015, Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial, Lancet sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm”
What the sources say
- Supportedcites [44] Wright, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med source
The Results section (Serious Adverse Events) explicitly reports that serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or acute renal failure occurred more frequently in the intensive-treatment group than in the standard-treatment group. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In individuals receiving ACE inhibitor or ARB therapy, continuation of those medications as kidney function declines to eGFR <30 mL/min/1.73 m2 may provide cardiovascular benefit without significantly increasing the risk of kidney failure (68).”
What the sources say
- Supportedcites [68] Qiao, 2020, Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate, JAMA Intern Med source
The Abstract reports that, among ACE-I or ARB users whose eGFR fell below 30 mL/min/1.73 m², discontinuation was associated with more major adverse cardiovascular events, while the difference in end-stage kidney disease risk was not statistically significant. Its conclusion explicitly suggests cardiovascular benefit from continuing therapy without excessive ESKD harm. (LLM, conf=0.94)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Use of internet or mobile-based digital platforms to reinforce healthy behaviors may be considered as a component of care, as these interventions have been found to enhance the efficacy of medical therapy for hypertension (55,56).”
What the sources say
- Partly supportedcites [55] Mao, 2020, Impact and efficacy of mobile health intervention in the management of diabetes and hypertension: a systematic review and meta-analysis, BMJ Open Diabetes Res Care sourceExperimental — accuracy not yet measured
The Results (Primary outcome of intervention; page unavailable) report greater reductions in systolic and diastolic blood pressure with mHealth interventions than with traditional treatment. The Results (Secondary results of intervention; page unavailable) also report changes in eating habits and physical activity. The paper does not establish that reinforcing those behaviors specifically enhances the efficacy of antihypertensive medication. (LLM, conf=0.82)
- Supportedcites [56] Stogios, 2020, Advancing digital health interventions as a clinically applied science for blood pressure reduction: a systematic review and meta-analysis, Can J Cardiol source
The Discussion (page not supplied) states that antihypertensive therapy was part of the intervention in 93% of trials and concludes that digital counselling improved the efficacy of medical therapy. It also reports a greater systolic blood-pressure reduction with digital interventions than with controls. (LLM, conf=0.94)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Absolute benefit from blood pressure reduction correlated with absolute baseline cardiovascular risk in SPRINT and in earlier clinical trials conducted at higher baseline blood pressure levels (50,51).”
What the sources say
- Supportedcites [50] Phillips, 2018, Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension, J Am Coll Cardiol source
The Results (Abstract; page unavailable) report that in SPRINT, the number needed to treat fell from 91 to 38 across increasing quartiles of baseline cardiovascular risk, indicating greater absolute benefit at higher risk. This paper supports the SPRINT portion of the sentence; the separate reference to earlier trials is not needed to establish that portion. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [51] Blood Pressure Lowering Treatment Trialists’ Collaboration., 2014, Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data, Lancet source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The trial showed the addition of ezetimibe to a moderate-intensity statin led to a 6.4% relative benefit and a 2% absolute reduction in major adverse cardiovascular events (atherosclerotic cardiovascular events), with the degree of benefit being directly proportional to the change in LDL cholesterol (112).”
What the sources say
- Supportedcites [112] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med source
The Efficacy End Points section reports a hazard ratio of 0.936 for the primary composite cardiovascular end point, equivalent to a 6.4% relative reduction, and a 2.0-percentage-point absolute risk reduction. The Discussion describes the event reduction as consistent with the degree of LDL-cholesterol lowering, while cautioning that the trial cannot prove LDL lowering alone mediated the benefit. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Multiple clinical trials have demonstrated the beneficial effects of statin therapy on ASCVD outcomes in subjects with and without established ASCVD (92,93).”
What the sources say
- Not checked — no full text of the sourcecites [92] Fulcher, 2015, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Lancet source
- Supportedcites [93] Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet source
The Results report reductions in major vascular events with statin therapy in participants both with previous vascular disease and with no history of it. The paper analyzes individual data from 27 randomized trials, supporting the claim that multiple trials demonstrated these benefits. (LLM, conf=0.93)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The addition of the PCSK9 monoclonal antibodies evolocumab and alirocumab to maximum tolerated doses of statin therapy in participants who were at high risk for ASCVD demonstrated an average reduction in LDL cholesterol ranging from 52% to 65% (120,121).”
What the sources say
- Not checked — no full text of the sourcecites [120] Moriarty, 2014, Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial, J Clin Lipidol source
- Partly supportedcites [121] Toth, 2022, Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol, J Am Heart Assoc sourceExperimental — accuracy not yet measured
The Results section (Primary Objective: Placebo-Corrected LDL-C Reduction at Week 12; page unavailable) reports substantial reductions with both antibodies: 62.80% for evolocumab, 64.80% for alirocumab 150 mg, and 53.97% for alirocumab 75 mg in a subgroup of trials whose populations were predominantly, not entirely, patients with ASCVD. This supports the general magnitude of the claimed range, but does not establish a 52% lower endpoint for these antibodies or that all participants were at high risk for ASCVD. (LLM, conf=0.83)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intensive therapy is indicated because cardiovascular event rates are increased in people with diabetes and established ASCVD, and it has been shown to be of benefit in multiple large meta-analyses and randomized cardiovascular outcomes trials (93,101,104,112,115).”
What the sources say
- Partly supportedcites [93] Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet sourceExperimental — accuracy not yet measured
The Results (page unavailable) say that the more-versus-less-intensive statin trials enrolled patients with previous coronary disease, and the Discussion reports that more intensive regimens further reduced major vascular events. The copy does not establish that this intensive-therapy benefit was demonstrated specifically in people with both diabetes and established ASCVD. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [101] Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet source
- Not checked — no full text of the sourcecites [104] Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Subgroup analyses of people with diabetes in larger trials (94–98) and trials in people with diabetes (99,100) showed significant primary and secondary prevention of ASCVD events and coronary heart disease (CHD) death in people with diabetes.”
What the sources say
- Not checked — no full text of the sourcecites [94] Pyŏrälä, 1997, Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), Diabetes Care source
- Not checked — no full text of the sourcecites [95] Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet source
- Partly supportedcites [96] Goldberg, 1998, Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators, Circulation sourceExperimental — accuracy not yet measured
The Results (page not supplied) report a significant 25% reduction in a composite of recurrent coronary events among patients with diabetes, supporting secondary prevention. But CARE studied myocardial infarction survivors, not primary prevention, and the Results say CHD death did not decline in the diabetes subgroup. (LLM, conf=0.90)
- Partly supportedcites [97] Shepherd, 2006, Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study, Diabetes Care sourceExperimental — accuracy not yet measured
The Efficacy outcomes section (page unavailable) reports a significant reduction in major cardiovascular events among patients with diabetes and established CHD, supporting the secondary-prevention portion. This study did not assess primary prevention, and its reduction in CHD death in the diabetes subgroup was not statistically significant (P = 0.203). (LLM, conf=0.88)
- Partly supportedcites [98] Sever, 2005, Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA), Diabetes Care sourceExperimental — accuracy not yet measured
In the Results passage labeled “Statistical methods” (page not provided), atorvastatin significantly reduced total cardiovascular events and procedures in the diabetic subgroup, including participants without preexisting cardiovascular disease. But the paper says the reduction in its primary endpoint of fatal CHD and nonfatal myocardial infarction was not statistically significant in that subgroup; Table 4 also shows no significant reduction in CHD death. This source therefore supports the cardiovascular-event portion, not the claim of significant prevention of CHD death. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [99] Knopp, 2006, Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN), Diabetes Care source
- Not checked — no full text of the sourcecites [100] Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intensive therapy is indicated because cardiovascular event rates are increased in people with diabetes and established ASCVD, and it has been shown to be of benefit in multiple large meta-analyses and randomized cardiovascular outcomes trials (93,101,104,112,115).”
What the sources say
- Partly supportedcites [93] Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet sourceExperimental — accuracy not yet measured
The Results link a history of vascular disease to higher predicted major vascular-event risk: almost all participants with predicted five-year risk of at least 20% came from trials of patients with prior vascular disease. The Discussion considers increased cardiovascular risk after a new diabetes diagnosis only as a hypothetical (“If new diagnoses of diabetes were associated with an immediate doubling”); it does not establish higher event rates in people with diabetes as the claim states. Page numbers are unavailable in our copy. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [101] Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet source
- Not checked — no full text of the sourcecites [104] Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The trial showed the addition of ezetimibe to a moderate-intensity statin led to a 6.4% relative benefit and a 2% absolute reduction in major adverse cardiovascular events (atherosclerotic cardiovascular events), with the degree of benefit being directly proportional to the change in LDL cholesterol (112).”
What the sources say
- Supportedcites [112] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med source
The Efficacy End Points section reports a 2.0-percentage-point absolute reduction in the primary cardiovascular end point with simvastatin–ezetimibe versus simvastatin alone. The paper describes 40 mg simvastatin as moderate-intensity background therapy; the result applies to patients after an acute coronary syndrome. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent data from the PCSK9 inhibitor trial FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) suggest that LDL cholesterol–lowering benefit has important cardiovascular risk reduction benefits in people with type 1 diabetes and established CVD, as discussed in secondary prevention (people with ascvd), below (114).”
What the sources say
- Supportedcites [114] Kang, 2025, Cardiovascular outcomes and efficacy of the PCSK9 inhibitor evolocumab in individuals with type 1 diabetes: insights from the FOURIER trial, Diabetes Care source
The Conclusions state that intensive LDL-C lowering may provide substantial clinical benefit in people with type 1 diabetes and established ASCVD. They also describe a trend toward reduced cardiovascular risk with evolocumab. The citing sentence's cautious 'suggest' reflects that uncertainty. (LLM, conf=0.91)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Monitoring lipid profiles after initiation of statin therapy and during therapy increases the likelihood of dose titration and following the statin treatment plan (88–90).”
What the sources say
- Not checked — no full text of the sourcecites [88] Jia, 2019, Association between lipid testing and statin adherence in the Veterans Affairs health system, Am J Med source
- Partly supportedcites [89] Rana, 2022, Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification, Am J Med sourceExperimental — accuracy not yet measured
The Results report that LDL-C testing after an ASCVD event was associated with higher statin adherence and treatment intensification. But the Discussion says the observational design cannot establish causation, and the study does not establish this effect for statin users generally after initiation or throughout therapy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [90] Tran, 2022, Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center, J Clin Lipidol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“As in those without diabetes, absolute reductions in ASCVD outcomes (CHD death and nonfatal MI) are greatest in people with high baseline ASCVD risk (known ASCVD and/or very high LDL cholesterol levels), but the overall benefits of statin therapy in people with diabetes at moderate or even low risk for ASCVD are convincing (102,103).”
What the sources say
- Not checked — no full text of the sourcecites [102] Taylor, 2013, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev source
- Could not verifycites [103] Carter, 2013, Risk of incident diabetes among patients treated with statins: population based study, BMJ sourceExperimental — accuracy not yet measured
The Introduction says statins have established benefits for patients at risk of cardiovascular events, but it does not compare absolute reductions across baseline-risk groups. The Results and Discussion address incident diabetes, not reductions in CHD death or nonfatal MI; searches for those outcomes and risk-specific benefits found no supporting passage in our copy. No page numbers were provided. (LLM, conf=0.76)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“These recommendations are based on the observation that high-intensity versus moderate-intensity statin therapy reduces cardiovascular event rates in high-risk individuals with established CVD in randomized trials (93).”
What the sources say
- Supportedcites [93] Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet source
The Results state that the trials comparing more- with less-intensive statin therapy were undertaken solely in patients with previous coronary disease. The Introduction reports that further LDL-cholesterol reductions with more-intensive regimens yielded further reductions in major vascular event risk. The paper uses “more versus less intensive,” rather than the exact labels “high-intensity versus moderate-intensity.” Page numbers were not provided for these passages. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A meta-analysis suggests that there is a cardiovascular benefit of adding ezetimibe or PCSK9 inhibitors to treatment for people at high risk (111).”
What the sources say
- Supportedcites [111] Khan, 2022, PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis, BMJ source
The Discussion (Principal findings) says that adding ezetimibe or a PCSK9 inhibitor to background lipid-lowering therapy may reduce non-fatal myocardial infarction and stroke in adults at high or very high cardiovascular risk. It also reports no significant effect on cardiovascular mortality, so the benefit is specific to those non-fatal outcomes. (LLM, conf=0.92)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The trial showed the addition of ezetimibe to a moderate-intensity statin led to a 6.4% relative benefit and a 2% absolute reduction in major adverse cardiovascular events (atherosclerotic cardiovascular events), with the degree of benefit being directly proportional to the change in LDL cholesterol (112).”
What the sources say
- Supportedcites [112] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med source
The Efficacy End Points section reports a 2.0-percentage-point absolute reduction in the primary outcome and a hazard ratio of 0.936, corresponding to a 6.4% relative reduction. The Discussion says the reduction in cardiovascular events was similar to that seen in prior trials according to the degree of LDL-cholesterol lowering. This is a comparison across trials, not proof that LDL lowering alone mediated the benefit. (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As in those without diabetes, absolute reductions in ASCVD outcomes (CHD death and nonfatal MI) are greatest in people with high baseline ASCVD risk (known ASCVD and/or very high LDL cholesterol levels), but the overall benefits of statin therapy in people with diabetes at moderate or even low risk for ASCVD are convincing (102,103).”
What the sources say
- Not checked — no full text of the sourcecites [102] Taylor, 2013, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev source
- Partly supportedcites [103] Carter, 2013, Risk of incident diabetes among patients treated with statins: population based study, BMJ sourceExperimental — accuracy not yet measured
The Introduction says statins have established benefits in patients at risk of cardiovascular events, supporting only the general benefit claim. The Methods (Cohort definition) exclude patients with established diabetes, and the paper does not establish cardiovascular benefits specifically for people with diabetes at moderate or low ASCVD risk. (LLM, conf=0.86)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Participants with type 1 diabetes randomly assigned to placebo had a higher rate of major cardiovascular events (Kaplan-Meier event rate 20.4%) than those with type 2 diabetes (15.2%) and those without diabetes (11.0%).”
What the sources say
- Supportedcites [114] Kang, 2025, Cardiovascular outcomes and efficacy of the PCSK9 inhibitor evolocumab in individuals with type 1 diabetes: insights from the FOURIER trial, Diabetes Care source
The Results section, under “Risk of MACE by Diabetes Type,” reports 2.5-year Kaplan–Meier rates for the primary cardiovascular end point in the placebo group: 20.4% for participants with type 1 diabetes, 15.2% for those with type 2 diabetes, and 11.0% for those without diabetes. This directly supports the comparison in the claim. (LLM, conf=0.95)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol [ORION-3]), where an LDL cholesterol reduction of ∼45% was maintained through the end of year 4 (133).”
What the sources say
- Supportedcites [133] Ray, 2023, Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial, Lancet Diabetes Endocrinol source
The Results table reports LDL cholesterol reductions of 46.7% in the inclisiran-only arm and 46.5% in the switching arm at day 1440. The Figure 2 caption identifies day 1440 as four years, supporting the paraphrase of an approximately 45% reduction through year 4. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When added to a maximally tolerated statin, these agents reduced LDL cholesterol by ∼60% (115) and significantly reduced the risk of major adverse cardiovascular events by 15–20% in the FOURIER (evolocumab) and ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trials (115,117,122).”
What the sources say
- Partly supportedcites [115] Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion reports that adding evolocumab to statin therapy in FOURIER significantly reduced the primary composite cardiovascular endpoint by 15% and the key secondary endpoint by 20%. The Trial Population section describes an optimized statin regimen, preferably high-intensity, but does not establish that every participant received a maximally tolerated dose. This paper reports FOURIER, not ODYSSEY OUTCOMES; the citing sentence supplies other citations for its combined trial claim. (LLM, conf=0.85)
- Supportedcites [117] Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med source
The End Points section reports a significantly lower composite cardiovascular event risk with alirocumab in ODYSSEY OUTCOMES (hazard ratio 0.85; P<0.001), a 15% relative reduction. The Trial Population section specifies high-intensity or maximum-tolerated statin treatment, and the Discussion says FOURIER showed similar improvements with the PCSK9 antibody evolocumab. The paper does not give a separate numerical estimate for FOURIER in these passages. (LLM, conf=0.87)
- Partly supportedcites [122] Giugliano, 2020, Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis, Stroke sourceExperimental — accuracy not yet measured
The Discussion (page unavailable in our copy) reports that evolocumab added to statin therapy reduced FOURIER’s primary cardiovascular composite by 15% and a narrower composite by 20%. The Study Population and Procedures section specifies moderate- or high-intensity statin therapy, not necessarily a maximally tolerated dose. This paper does not report the claimed 15–20% result for ODYSSEY OUTCOMES. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similar LDL cholesterol reductions were demonstrated in the GAUSS 3 trial after 24 weeks (54.5% with evolocumab compared with 16.7% with ezetimibe), with slightly higher rates of musculoskeletal adverse events (20.7% with evolocumab and 28.8% with ezetimibe).”
What the sources say
- Partly supportedcites [131] Nissen, 2016, Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial, JAMA sourceExperimental — accuracy not yet measured
Table 3 (Coprimary End Points) reports LDL-C reductions of 54.5% with evolocumab and 16.7% with ezetimibe for the mean of weeks 22 and 24. At week 24 specifically, the reductions were 52.8% and 16.7%, respectively, so the claim assigns the evolocumab figure to a more specific time point than the paper does. (LLM, conf=0.88)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For individuals requiring primary prevention, the use of bempedoic acid resulted in a 30% reduction in primary composite outcome compared with placebo (137).”
What the sources say
- Partly supportedcites [137] Nissen, 2023, Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients, JAMA sourceExperimental — accuracy not yet measured
The Clinical End Points section reports a primary composite outcome hazard ratio of 0.70 for bempedoic acid versus placebo, supporting the stated 30% relative reduction. The Study Population and Conclusion sections limit this finding to high-risk primary prevention patients unable to tolerate recommended statin doses; the claim does not retain those population qualifiers. (LLM, conf=0.83)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“After the 24 weeks, alirocumab lowered LDL cholesterol levels by 54.8% versus 20.1% with ezetimibe.”
What the sources say
- Supportedcites [128] Moriarty, 2015, Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial, J Clin Lipidol source
The figure text reproduced in the Safety and tolerability passage gives week-24 LDL-C reductions of 54.8% for alirocumab and 20.1% for ezetimibe. These match the claim; they are distinct from the primary intent-to-treat estimates reported in Efficacy. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The relative reduction in the risk of the primary major adverse cardiovascular event outcome with active compared with placebo evolocumab was similar across different types or statuses of diabetes (type 1 diabetes HR 0.66, 95% CI 0.32–1.38; type 2 diabetes HR 0.84, 95% CI 0.75–0.93; no diabetes HR 0.87, 95% CI 0.79–0.96).”
What the sources say
- Partly supportedcites [114] Kang, 2025, Cardiovascular outcomes and efficacy of the PCSK9 inhibitor evolocumab in individuals with type 1 diabetes: insights from the FOURIER trial, Diabetes Care sourceExperimental — accuracy not yet measured
The Results (page unavailable) report exactly the three cited hazard ratios and confidence intervals for the primary outcome. However, they describe the relative risk reduction as numerically greater in type 1 diabetes (34% versus 16% and 13%), rather than similar across groups. The Conclusions note that the small type 1 diabetes group limited power to detect differences between groups. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition to the monoclonal antibodies, an siRNA, inclisiran, which also targets PSCK9 and is referred to as a PCSK9 siRNA in this section, has demonstrated the ability to reduce LDL cholesterol by 49–52% in trials evaluating individuals with established CVD or ASCVD risk equivalent (123).”
What the sources say
- Supportedcites [123] Ray, 2020, Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol, N Engl J Med source
The Patients section (p. 2) says ORION-10 enrolled people with established atherosclerotic cardiovascular disease (ASCVD), while ORION-11 also enrolled people with an ASCVD risk equivalent. The Efficacy section (p. 5) reports placebo-adjusted LDL cholesterol reductions of 52.3% and 49.9% at day 510, consistent with the cited 49–52% range. (LLM, conf=0.93)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similar LDL cholesterol reductions were demonstrated in the GAUSS 3 trial after 24 weeks (54.5% with evolocumab compared with 16.7% with ezetimibe), with slightly higher rates of musculoskeletal adverse events (20.7% with evolocumab and 28.8% with ezetimibe).”
What the sources say
- Supportedcites [131] Nissen, 2016, Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial, JAMA source
Table 4 (Conclusions section) reports total muscle-related events in 30 of 145 evolocumab patients (20.7%) and 21 of 73 ezetimibe patients (28.8%). These match the rates attributed to GAUSS-3. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“These observations suggest that the absolute risk reduction of major cardiovascular events with evolocumab in individuals with type 1 diabetes was at least as large, if not larger, than that seen for type 2 diabetes or no diabetes.”
What the sources say
- Supportedcites [114] Kang, 2025, Cardiovascular outcomes and efficacy of the PCSK9 inhibitor evolocumab in individuals with type 1 diabetes: insights from the FOURIER trial, Diabetes Care source
The Results report a numerically greater absolute risk reduction in the type 1 diabetes group: 7.31%, compared with 2.53% for type 2 diabetes and 1.27% for no diabetes. The citing sentence’s tentative wording is consistent with a numerical comparison, particularly given the wide confidence interval for the type 1 diabetes estimate. (LLM, conf=0.93)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Prespecified subanalyses evaluated the impact for individuals with diabetes and showed a 17% reduction in four-point major adverse cardiovascular events when treated with bempedoic acid (136).”
What the sources say
- Supportedcites [136] Ray, 2024, Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial, Lancet Diabetes Endocrinol source
The Discussion reports that this prespecified CLEAR Outcomes analysis found a 17% reduction in MACE-4 events with bempedoic acid among patients with diabetes. The Results give the corresponding hazard ratio of 0.83 (95% CI 0.72–0.95). (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When added to a maximally tolerated statin, these agents reduced LDL cholesterol by ∼60% (115) and significantly reduced the risk of major adverse cardiovascular events by 15–20% in the FOURIER (evolocumab) and ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trials (115,117,122).”
What the sources say
- Partly supportedcites [115] Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion reports that adding evolocumab to statin therapy lowered LDL cholesterol by 59% versus placebo, supporting the approximate 60% figure. The Trial Population section describes an optimized statin regimen, preferably high-intensity but permitting at least atorvastatin 20 mg daily or equivalent; it does not establish that every patient was taking a maximally tolerated dose. The trial directly tested evolocumab, not PCSK9 monoclonal antibodies as a group. Page numbers are not available in our copy. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Use of this agent with ezetimibe results in an additional 19% reduction in LDL cholesterol (134).”
What the sources say
- Supportedcites [134] De Filippo, 2023, Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials, Cardiovasc Diabetol source
The Results report that, across four studies, adding bempedoic acid to background ezetimibe therapy was associated with a mean 19.03% reduction in LDL-C. This supports the claimed additional 19% reduction; it does not mean ezetimibe adds 19% to the effect of bempedoic acid. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although the evidence is limited, statins did not increase teratogenic effects for individuals with familial hypercholesterolemia (141,142), and a meta-analysis of pravastatin in pregnant individuals showed a reduction in preeclampsia, premature birth, and neonatal intensive care unit admissions (143).”
What the sources say
- Not checked — no full text of the sourcecites [141] Botha, 2018, Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: a retrospective review of 39 pregnancies, Atherosclerosis source
- Partly supportedcites [142] Toleikyte, 2011, Pregnancy outcomes in familial hypercholesterolemia: a registry-based study, Circulation sourceExperimental — accuracy not yet measured
The Congenital Malformations section reports no significant change in malformation frequency among women with familial hypercholesterolemia before versus after statins were introduced, and no malformations among 19 women who took lipid-lowering drugs during pregnancy. The Prematurity, Drug Use, and Mutation Types section identifies 15 of those women as statin users. These limited observations do not establish that statin exposure itself did not increase teratogenic risk. (LLM, conf=0.82)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“In ARRIVE, with 12,546 individuals over a period of 60 months of follow-up, the primary end point occurred in 4.29% vs. 4.48% of individuals in the aspirin versus placebo groups (HR 0.96 [95% CI 0.81–1.13]; P = 0.60).”
What the sources say
- Supportedcites [174] Gaziano, 2018, Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial, Lancet source
The Results report primary-endpoint rates of 4.29% with aspirin and 4.48% with placebo, with HR 0.96 (95% CI 0.81–1.13) and p=0.6038, rounded to 0.60 in the claim. The Results also report 12,546 participants and approximately 60 months of follow-up. Page numbers were not supplied. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the ACCORD study, in people with type 2 diabetes who were at high risk for ASCVD, the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal MI, or nonfatal stroke compared with simvastatin alone (153).”
What the sources say
- Supportedcites [153] Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (154) and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (155).”
What the sources say
- Supportedcites [154] Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med source
The Primary and Secondary End Points section reports more ischemic strokes among patients assigned to niacin than placebo (29 versus 18), but calls the difference a nonsignificant trend. The Discussion says the authors could not determine whether it was causal or due to chance, consistent with the claim’s cautious wording. (LLM, conf=0.94)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, they found that aspirin reduced the risk of serious vascular events by 12% (relative risk 0.88 [95% CI 0.82–0.94]).”
What the sources say
- Supportedcites [172] Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet source
The Results report that aspirin produced a 12% proportional reduction in serious vascular events in the primary-prevention trials, with a rate ratio of 0.88 (95% CI 0.82–0.94). The Methods describe six primary-prevention trials involving 95,000 individuals. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In primary prevention, however, among individuals with no previous cardiovascular events, its net benefit is more controversial (156,168).”
What the sources say
- Could not verifycites [156] Rajpathak, 2009, Statin therapy and risk of developing type 2 diabetes: a meta-analysis, Diabetes Care sourceExperimental — accuracy not yet measured
The Results and Conclusions (page unavailable) discuss statin trials, cardiovascular prevention, and diabetes risk, not aspirin. Searches for aspirin’s net benefit and bleeding risk in primary prevention found no passage addressing the claim. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [168] Perk, 2012, European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts), Eur Heart J source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“During a mean follow-up of 7.4 years, there was a significant 12% reduction in the primary efficacy end point (8.5% vs. 9.6%; P = 0.01).”
What the sources say
- Supportedcites [173] Bowman, 2018, Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med source
The Methods (p. 1) define the primary efficacy outcome as myocardial infarction, stroke or transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage. The Results (p. 1) report a mean follow-up of 7.4 years and event rates of 8.5% versus 9.6% (rate ratio 0.88; P = 0.01), supporting the stated 12% reduction. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, no change in cognitive function has been reported in studies with the addition of ezetimibe (112) or PCSK9 monoclonal antibodies (115,164) to statin therapy, including among individuals treated to very low LDL cholesterol levels.”
What the sources say
- Could not verifycites [112] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med sourceExperimental — accuracy not yet measured
The End Points section lists the trial’s prespecified safety measures but does not include cognitive function. The Lipid Data and Discussion sections report LDL lowering with ezetimibe and no significant differences in the specified safety end points, but neither reports cognitive outcomes, including among patients with very low LDL levels. Searched for cognitive function, neurocognitive impairment, and memory; this citation is attached to the ezetimibe part of the sentence, not the PCSK9 part. (LLM, conf=0.77)
- Partly supportedcites [115] Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med sourceExperimental — accuracy not yet measured
The Results report no significant difference in neurocognitive events between evolocumab and placebo when added to statin therapy; Table 3 gives rates of 1.6% and 1.5%. The paper also reports a median LDL cholesterol level of 30 mg/dL with evolocumab. It does not report a direct measure of cognitive function or a separate cognitive analysis of patients who reached very low LDL levels. (LLM, conf=0.82)
- Supportedcites [164] Giugliano, 2017, Cognitive function in a randomized trial of evolocumab, N Engl J Med source
The Conclusions report no significant difference in cognitive function between evolocumab and placebo when each was added to statin therapy over a median of 19 months. The Discussion adds that this held even among patients who attained very low LDL cholesterol levels. This source supports the PCSK9-inhibitor portion of the sentence; the ezetimibe portion has a separate citation. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The absolute risk increase was small (over 5 years of follow-up, 1.2% of participants on placebo developed diabetes and 1.5% on rosuvastatin developed diabetes) (158).”
What the sources say
- Partly supportedcites [158] Ridker, 2012, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial, Lancet sourceExperimental — accuracy not yet measured
The Results report more incident diabetes with rosuvastatin than placebo (270 versus 216 cases), supporting a small absolute increase. But the paper does not report that 1.5% and 1.2% of participants developed diabetes over five years: the Methods say follow-up was up to five years, and the Discussion says median follow-up was two years. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (160–163).”
What the sources say
- Not checked — no full text of the sourcecites [160] Heart Protection Study Collaborative Group, 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet source
- Not checked — no full text of the sourcecites [161] Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet source
- Not checked — no full text of the sourcecites [162] Trompet, 2010, Pravastatin and cognitive function in the elderly. Results of the PROSPER study, J Neurol source
- Partly supportedcites [163] Yusuf, 2016, Cholesterol lowering in intermediate-risk persons without cardiovascular disease, N Engl J Med sourceExperimental — accuracy not yet measured
The Methods (p. 1) describe a large randomized trial comparing rosuvastatin with placebo. The available passages report cardiovascular outcomes, not specific cognitive tests or cognitive results, so they do not support the claimed absence of a cognitive difference. This paper also cannot by itself establish the sentence’s count of three trials. (LLM, conf=0.79)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
What the sources say
- Partly supportedcites [154] Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion reports that AIM-HIGH found no incremental cardiovascular benefit from adding niacin to intensive statin therapy. It describes HPS2-THRIVE as still in follow-up, so this paper does not support the claim that HPS2-THRIVE had also failed to demonstrate a benefit. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [155] Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, systematic reviews of randomized controlled trials and prospective cohort studies evaluating cognition in individuals receiving statins found that published data do not reveal an adverse effect of statins on cognition (165,166).”
What the sources say
- Partly supportedcites [165] Olmastroni, 2022, Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies, Eur J Prev Cardiol sourceExperimental — accuracy not yet measured
The Introduction says short-term data suggest no adverse effect of statins on cognition, and the Discussion reports no worsening of cognitive decline in several randomized trials. However, the Studies selection section says this review included observational cohort and case-control studies of Alzheimer's disease or dementia risk—not randomized trials or cognition outcomes generally. The claim's description of what this review evaluated is therefore not supported. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [166] Richardson, 2013, Statins and cognitive function: a systematic review, Ann Intern Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk individuals with previous MI or stroke (secondary prevention) and is strongly recommended.”
What the sources say
- Could not verifycites [156] Rajpathak, 2009, Statin therapy and risk of developing type 2 diabetes: a meta-analysis, Diabetes Care sourceExperimental — accuracy not yet measured
The Results section reports cardiovascular outcomes for statin trials, including secondary-prevention trials, but does not address aspirin. Searches for aspirin, prior MI or stroke, and secondary-prevention recommendations found no passage supporting the attributed claim. Page numbers were not available in our copy. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [168] Perk, 2012, European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts), Eur Heart J source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although concerns regarding a potential adverse impact of lipid-lowering agents on cognitive function have been raised, several lines of evidence argue against this association, as detailed in a 2018 European Atherosclerosis Society Consensus Panel statement (159).”
What the sources say
- Supportedcites [159] Mach, 2018, Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract, Eur Heart J source
The Take home messages (p. 10) state that statins do not adversely affect cognitive function and report no adverse cognitive signal at very low LDL-C levels reached with statins plus ezetimibe or a PCSK9 inhibitor. The Cognitive function section (pp. 8–10) cites trial, meta-analysis and observational evidence, matching the claim that several lines of evidence argue against the proposed association. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“An analysis of one of the initial studies suggested that although statin use was associated with diabetes risk, the cardiovascular event rate reduction with statins far outweighed the risk of incident diabetes, even for individuals at highest risk for diabetes (158).”
What the sources say
- Supportedcites [158] Ridker, 2012, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial, Lancet source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The screening of asymptomatic individuals with high ASCVD risk is not recommended, in part because these high-risk people should already be receiving intensive medical therapy—an approach that provides benefits similar to those of invasive revascularization (197,198).”
What the sources say
- Not checked — no full text of the sourcecites [197] Boden, 2007, Optimal medical therapy with or without PCI for stable coronary disease, N Engl J Med source
- Partly supportedcites [198] Frye, 2009, A randomized trial of therapies for type 2 diabetes and coronary artery disease, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion reports similar overall outcomes with intensive medical therapy and prompt revascularization in patients with type 2 diabetes and stable ischemic heart disease. It does not establish the same result for high-risk asymptomatic individuals generally: the Results (Patients; page not provided) say 82.1% had symptomatic ischemia, and the Discussion reports fewer major cardiovascular events with prompt revascularization in patients selected for CABG. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The rate of major hemorrhage per 1,000 person-years was 8.6 events versus 6.2 events, respectively (HR 1.38 [95% CI 1.18–1.62]; P < 0.001).”
What the sources say
- Supportedcites [175] McNeil, 2018, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl J Med source
The Results section (“Major Hemorrhagic Events”) reports 8.6 major hemorrhages per 1,000 person-years in the aspirin group versus 6.2 in the placebo group, with the stated hazard ratio, confidence interval, and P value. The paper identifies these findings as from ASPREE. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Gastrointestinal bleeding events (characterized as mild) occurred in 0.97% of individuals in the aspirin group vs. 0.46% in the placebo group (HR 2.11 [95% CI 1.36–3.28]; P = 0.0007).”
What the sources say
- Supportedcites [174] Gaziano, 2018, Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial, Lancet source
The Results report gastrointestinal bleeding in 61 aspirin patients (0.97%) versus 29 placebo patients (0.46%), with HR 2.11, 95% CI 1.36–3.28, and p=0.0007. The same passage says the events were predominantly mild. (LLM, conf=0.95)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“People with diabetes are at an increased risk for developing heart failure, as shown in multiple longitudinal, observational studies (205,206).”
What the sources say
- Supportedcites [205] McAllister, 2018, Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus, Circulation source
The Conclusion (page not supplied) reports that heart failure incidence remains approximately twofold higher in people with diabetes than in those without it. The Discussion (page not supplied) also describes elevated risk in the REACH registry and a higher rate of incident heart failure hospitalization in a Swedish population-based study, supporting the reference to multiple observational studies. (LLM, conf=0.92)
- Supportedcites [206] Ohkuma, 2019, Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals, Diabetologia source
The Methods describe a meta-analysis of observational cohort studies, and the Results report higher heart-failure risk in people with type 1 or type 2 diabetes than in those without diabetes. This supports the claim that multiple longitudinal observational studies show an increased risk. (LLM, conf=0.94)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, an increased risk of major bleeding was noted with rivaroxaban added to aspirin treatment in both COMPASS and VOYAGER PAD.”
What the sources say
- Partly supportedcites [194] Bhatt, 2020, Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial, Circulation sourceExperimental — accuracy not yet measured
The Results section reports a significant increase in major bleeding with rivaroxaban plus aspirin versus aspirin alone in COMPASS. Our copy reports no VOYAGER PAD bleeding result, so it does not support the claim about both trials (searched: “VOYAGER PAD” and “VOYAGER”). (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [195] Connolly, 2018, Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial, Lancet source
- Partly supportedcites [196] Bonaca, 2020, Rivaroxaban in peripheral artery disease after revascularization, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract and Discussion report significantly more ISTH-defined major bleeding with rivaroxaban plus aspirin in VOYAGER PAD, but no significant difference in the principal TIMI-defined major-bleeding outcome. The Introduction and discussion of COMPASS describe its ischemic benefits, not an increased risk of major bleeding, so our copy does not support that part of the claim. (LLM, conf=0.87)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In ASPREE, which included 19,114 individuals, for CVD (fatal CHD, MI, stroke, or hospitalization for heart failure) after a median of 4.7 years of follow-up, the rates per 1,000 person-years were 10.7 vs. 11.3 events in aspirin vs. placebo groups (HR 0.95 [95% CI 0.83–1.08]).”
What the sources say
- Supportedcites [175] McNeil, 2018, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl J Med source
The Methods (Cardiovascular Events; page not provided) define the CVD composite as fatal coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart failure. The Results (Participants and Follow-up; Cardiovascular Events; pages not provided) report 19,114 participants, median follow-up of 4.7 years, and the stated aspirin-versus-placebo rates and hazard ratio. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This association is not only observed in people with type 2 diabetes but also evident in people with type 1 diabetes (205,206).”
What the sources say
- Supportedcites [205] McAllister, 2018, Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus, Circulation source
The Discussion reports elevated heart-failure incidence in people with type 2 diabetes and an increased risk in people with type 1 diabetes, each compared with people without diabetes. The Conclusion likewise states that heart failure remains approximately twofold higher in people with diabetes than in those without it. (LLM, conf=0.92)
- Supportedcites [206] Ohkuma, 2019, Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals, Diabetologia source
The Discussion states that this meta-analysis provides evidence that both type 1 and type 2 diabetes are risk factors for heart failure in both sexes. The Results report elevated pooled relative risks for each diabetes type in women and men. (LLM, conf=0.94)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Studies have also found that a risk factor–based approach to the initial diagnostic evaluation and subsequent follow-up for coronary artery disease fails to identify which people with type 2 diabetes who will have silent ischemia on screening tests (201,202).”
What the sources say
- Partly supportedcites [201] Wackers, 2004, Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study, Diabetes Care sourceExperimental — accuracy not yet measured
The Clinical implications section (p. 6) says the two-or-more-risk-factor screening recommendation missed many patients with test abnormalities, supporting the claim about initial screening. It also says these data address only silent ischemia at enrollment and that follow-up evaluation was still planned; this paper does not establish the claim about subsequent follow-up. (LLM, conf=0.87)
- Partly supportedcites [202] Scognamiglio, 2006, Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
The Abstract reports nearly identical rates of abnormal stress screening in asymptomatic patients with type 2 diabetes regardless of risk-factor profile, supporting the claim about initial screening. The Discussion says the five-year follow-up was still pending, so this paper does not establish that a risk factor–based approach fails during subsequent follow-up. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“People with diabetes are at particularly high risk for progression from asymptomatic stage A and B to symptomatic stage C and D heart failure (208,209).”
What the sources say
- Partly supportedcites [208] Segar, 2020, Association of long-term change and variability in glycemia with risk of incident heart failure among patients with type 2 diabetes: a secondary analysis of the ACCORD trial, Diabetes Care sourceExperimental — accuracy not yet measured
The Study Population section (p. 3) says participants had type 2 diabetes and no history of heart failure, and the outcome section (p. 3) tracks incident heart failure. The paper also says heart failure is common in adults with type 2 diabetes (Conclusions, p. 2). It does not establish a particularly high risk relative to people without diabetes or assess progression through stages A/B to C/D. (LLM, conf=0.84)
- Supportedcites [209] Echouffo-Tcheugui, 2022, Diabetes and progression of heart failure: the Atherosclerosis Risk In Communities (ARIC) study, J Am Coll Cardiol source
The Discussion states that diabetes was associated with increased risk of progression from preclinical stages A and B to symptomatic heart failure. The Conclusion likewise reports substantial excess risk of progression to overt heart failure in both stages among older Black and White adults with uncontrolled diabetes. (LLM, conf=0.92)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A randomized trial demonstrated no clinical benefit of routine screening with adenosine-stress radionuclide myocardial perfusion imaging in asymptomatic people with type 2 diabetes and normal ECGs (199).”
What the sources say
- Supportedcites [199] Young, 2009, Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial, JAMA source
The Methods section describes random assignment to adenosine-stress radionuclide MPI or no screening and excludes patients with specified abnormal resting ECG findings. The Comment section reports that screening had no discernible effect on subsequent cardiac events in asymptomatic patients with type 2 diabetes. (LLM, conf=0.93)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial of 27,395 individuals with established coronary artery disease and/or PAD, aspirin plus rivaroxaban 2.5 mg twice daily was superior to aspirin plus placebo in the reduction of cardiovascular ischemic events, including major adverse limb events.”
What the sources say
- Supportedcites [194] Bhatt, 2020, Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial, Circulation source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [195] Connolly, 2018, Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a large multinational cohort of 750,000 people with diabetes without established CVD, heart failure and CKD were the most frequent first manifestations of cardiovascular or kidney disease (207).”
What the sources say
- Supportedcites [207] Birkeland, 2020, Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study, Diabetes Obes Metab source
The Results (First CVRD manifestation) report that, among 772,336 initially cardiovascular- or renal-disease-free patients with type 2 diabetes, HF and CKD accounted for 24% and 36% of first manifestations, respectively—more than any other listed condition. The claim rounds the cohort size and describes the baseline group as without established CVD; the paper specifies the narrower condition of being free of cardiovascular or renal disease. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Rivaroxaban treatment in this group of individuals was also associated with a significantly lower incidence of ischemic cardiovascular events, including major adverse limb events.”
What the sources say
- Supportedcites [196] Bonaca, 2020, Rivaroxaban in peripheral artery disease after revascularization, N Engl J Med source
The Abstract reports that, among patients with peripheral artery disease after lower-extremity revascularization, rivaroxaban 2.5 mg twice daily plus aspirin significantly reduced the primary composite outcome compared with placebo plus aspirin (17.3% versus 19.9% at 3 years; P = 0.009). That composite included acute limb ischemia and major amputation for vascular causes, alongside cardiovascular events. The finding concerns the composite outcome, not a significant reduction in every component individually. (LLM, conf=0.93)
plaincorrelationaln = 6,564- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness) trial of individuals with established CVD, 38% of whom had diabetes, there were no significant differences in cardiovascular events or major bleeding between individuals assigned to 81 mg and those assigned to 325 mg aspirin daily (185).”
What the sources say
- Partly supportedcites [185] Jones, 2021, Comparative effectiveness of aspirin dosing in cardiovascular disease, N Engl J Med sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For people >70 years of age (with or without diabetes), the balance appears to have greater risk than benefit (173,175).”
What the sources say
- Partly supportedcites [173] Bowman, 2018, Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med sourceExperimental — accuracy not yet measured
The Conclusions (p. 1) say that, among people with diabetes and no evident cardiovascular disease, aspirin’s benefits were largely counterbalanced by major bleeding. The paper does not establish that risks exceed benefits specifically for people over 70, with or without diabetes; its reported balance is closer to even than the claim suggests. (LLM, conf=0.84)
- Partly supportedcites [175] McNeil, 2018, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl J Med sourceExperimental — accuracy not yet measured
The Conclusions report more major hemorrhage without a significant reduction in cardiovascular disease, and the Results report no evidence that the cardiovascular or bleeding effects differed by diabetes subgroup (page not provided). But the trial studied aspirin for primary prevention in largely healthy older adults, not all people over 70; the paper notes that aspirin’s benefits can outweigh hemorrhage risk in secondary prevention. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The absolute benefits of combination therapy appeared larger in people with diabetes, who comprised 10,341 of the trial participants (194,195).”
What the sources say
- Supportedcites [194] Bhatt, 2020, Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial, Circulation source
The Results report that absolute risk reductions with rivaroxaban plus aspirin appeared larger in patients with diabetes than in those without it. The Results also state that 10,341 of the 27,395 COMPASS participants had diabetes; 6,922 of those were in the two arms used for this comparison. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [195] Connolly, 2018, Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial, Lancet source
hedgedcorrelationaln = 10,341- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, the presence of microvascular disease is associated with adverse outcomes in people with PAD, including an increased risk for future limb amputation (228,229).”
What the sources say
- Supportedcites [228] Beckman, 2019, Microvascular disease, peripheral artery disease, and amputation, Circulation source
The Results (Amputation; page not provided) report that participants with both PAD and microvascular disease had a higher adjusted risk of incident amputation than those with PAD alone, with each compared against participants with neither condition. The Discussion also describes an additive effect of microvascular disease on adverse limb outcomes in PAD. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [229] Olesen, 2022, Microvascular disease increases the risk of lower limb amputation–a Western Danish cohort study, Eur J Clin Invest source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The risk for PAD in people with diabetes is higher than that in people without diabetes (220–222).”
What the sources say
- Supportedcites [220] Selvin, 2004, Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000, Circulation source
The Prevalence of PAD section reports PAD in 10.8% of individuals with diabetes versus 3.6% of those without diabetes. The study concerns US adults aged 40 and older; within that population, it supports the citing sentence's comparison. (LLM, conf=0.93)
- Supportedcites [221] Leibson, 2004, Peripheral arterial disease, diabetes, and mortality, Diabetes Care source
The introduction states that individuals with diabetes were at significantly increased risk of developing PAD. The paper’s conclusions also identify diabetes as a risk factor for PAD. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [222] Murabito, 1997, Intermittent claudication. A risk profile from The Framingham Heart Study, Circulation source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Cardiovascular outcome trials of ertugliflozin and bexagliflozin have not demonstrated evidence of cardiovascular risk reduction (249,250).”
What the sources say
- Not checked — no full text of the sourcecites [249] Cannon, 2020, Cardiovascular outcomes with ertugliflozin in type 2 diabetes, N Engl J Med source
- Supportedcites [250] McMurray, 2024, Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin, Diabetes Obes Metab source
The Discussion states that bexagliflozin did not establish superiority for reducing cardiovascular risk. Table 3 in the Discussion also reports an ertugliflozin MACE hazard ratio of 0.97 (95% CI 0.85–1.11), which does not demonstrate a reduction. The claim is supported as a statement about the absence of demonstrated superiority, not the absence of favourable point estimates. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While a positive screening test for PAD in an asymptomatic population has been associated with increased cardiovascular event rates (230,231), prospective, randomized studies addressing whether screening for PAD in”
What the sources say
- Partly supportedcites [230] Smolderen, 2022, Peripheral artery disease screening in the community and 1-year mortality, cardiovascular events, and adverse limb events, AJPM Focus sourceExperimental — accuracy not yet measured
The Results report higher major adverse cardiovascular event rates after a positive PAD screen than after a negative screen. The Discussion describes participants as previously unknown to have PAD, but does not establish that the screened population was asymptomatic; that qualifier is not supported. (LLM, conf=0.85)
- Supportedcites [231] Smolderen, 2022, The Nevada peripheral artery disease screening effort in a Medicare Advantage population and subsequent mortality and major adverse cardiovascular event risk, J Vasc Surg source
The Conclusions describe asymptomatic lower-extremity PAD detected through population-wide screening as associated with increased major adverse cardiovascular event (MACE) risk. The reported results show higher 3-year MACE risk after a positive versus negative screen, including after adjustment. The studied population was Medicare Advantage beneficiaries aged 65 or older in the Las Vegas area; page numbers are not provided in our copy. (LLM, conf=0.94)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“ACE inhibitors or ARB therapy also have well-established long-term benefit in people with diabetes and CKD or hypertension, and these agents are recommended for hypertension management in people with known ASCVD (particularly coronary artery disease) (66,67,238).”
What the sources say
- Partly supportedcites [66] Arnold, 2020, Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association, Circulation sourceExperimental — accuracy not yet measured
In Blood Pressure Control (page unavailable), the statement recommends ACE inhibitors or ARBs for hypertension in patients with type 2 diabetes and coronary artery disease, and reports renal benefit in patients with albuminuria. It also describes cardiovascular benefits over 4.5 years in a diabetes trial. The claim extends the kidney benefit to people with diabetes and CKD generally, whereas the passage specifies albuminuria. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [67] Yusuf, 2008, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial, Lancet source
- Not checked — no full text of the sourcecites [238] Braunwald, 2004, Angiotensin-converting-enzyme inhibition in stable coronary artery disease, N Engl J Med source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (211,216,217).”
What the sources say
- Partly supportedcites [211] Huelsmann, 2013, PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [216] Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Results (statistical analysis; page not available) report fewer cardiovascular events with intensive multifactorial treatment, supporting the broad risk-reduction point. But the trial enrolled patients with type 2 diabetes and microalbuminuria, not people selected for elevated natriuretic peptides; its listed outcomes do not establish reductions in symptomatic heart failure, heart-failure hospitalization, or newly diagnosed left ventricular dysfunction. (LLM, conf=0.84)
- Partly supportedcites [217] Gaede, 2005, Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria, Diabetologia sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Results of large cardiovascular outcome trials of empagliflozin (10 mg or 25 mg daily) and canagliflozin (100 or 300 mg daily) showed that treatment with either drug reduced rates of MI, stroke, or cardiovascular death.”
What the sources say
- Partly supportedcites [247] Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Cardiovascular Outcomes section reports that canagliflozin reduced the composite rate of cardiovascular death, nonfatal MI, or nonfatal stroke, and the Randomization section confirms the 100 mg and 300 mg doses. This paper does not report the empagliflozin trial’s results or substantiate its stated doses; it only references that trial. It also says the individual canagliflozin outcome components did not reach statistical significance. (LLM, conf=0.86)
- Partly supportedcites [248] Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says the canagliflozin CANVAS results were consistent with lower rates of the composite of cardiovascular death, myocardial infarction, or stroke, and that EMPA-REG OUTCOME showed empagliflozin was superior to placebo. This supports the main cardiovascular-outcome claim, but our copy does not establish the specific daily doses stated in the citing sentence. (LLM, conf=0.82)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Identification, risk stratification, and early treatment of risk factors in people with diabetes and asymptomatic stages of heart failure reduce the risk for progression to symptomatic heart failure (210,211).”
What the sources say
- Not checked — no full text of the sourcecites [210] Ledwidge, 2013, Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial, JAMA source
- Partly supportedcites [211] Huelsmann, 2013, PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
The Abstract describes NT-proBNP risk selection and intensified treatment in people with type 2 diabetes who were free of cardiac disease, and reports fewer cardiac hospitalizations or deaths. The Conclusions table also shows fewer heart-failure hospitalizations (1 versus 7), but the Cox-model estimate for that endpoint was not statistically significant (p = 0.07). The paper did not establish that participants had asymptomatic-stage heart failure or directly measure progression to symptomatic heart failure. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Results of trials with the GLP-1 RAs liraglutide (once daily) and semaglutide, albiglutide, efpeglenatide, and dulaglutide (once weekly) have all shown evidence of a reduction in major atherosclerotic cardiovascular outcomes (MI, stroke, or cardiovascular death) (251–256).”
What the sources say
- Supportedcites [251] Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med source
This citation supports the liraglutide portion of the multi-citation sentence. The Discussion reports a lower risk of the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke with liraglutide than with placebo; Methods > Procedures specifies once-daily dosing. The other named drugs are not attributed to this trial alone. (LLM, conf=0.94)
- Supportedcites [252] Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med source
The cited SUSTAIN-6 paper supports the semaglutide portion of this multi-cited sentence. Its Cardiovascular Outcomes section reports a lower rate of the composite of cardiovascular death, nonfatal MI, or nonfatal stroke with semaglutide than with placebo; the Conclusions section identifies semaglutide as suitable for once-weekly administration. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [253] Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet source
- Supportedcites [254] Gerstein, 2021, Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes, N Engl J Med source
For the efpeglenatide portion of this multiply cited sentence, the Methods (p. 1) define MACE as nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or undetermined causes. Trial Outcomes (p. 5) report a lower MACE rate with weekly efpeglenatide than with placebo. This citation need not establish the results for the other drugs, which the sentence cites separately. (LLM, conf=0.93)
- Supportedcites [255] Lee, 2025, Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials, Diabetes Care source
Table 1 identifies trials of liraglutide, semaglutide, albiglutide, efpeglenatide, and dulaglutide and lists the stated injection schedules. The Results report that long-acting GLP-1 receptor agonists reduced three-point MACE—cardiovascular death, myocardial infarction, or stroke—and the Conclusions say the benefits appeared consistent across most trials. This supports the claim of evidence of reduction, though the paper does not say every individual trial showed a statistically significant reduction. (LLM, conf=0.87)
- Supportedcites [256] Hernandez, 2018, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial, Lancet source
The citation is one of several attached to different GLP-1 receptor agonist trials; this paper supports the albiglutide portion. The Discussion reports that once-weekly albiglutide reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 22% versus placebo in patients with type 2 diabetes and cardiovascular disease. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In people with type 2 diabetes, measurement of natriuretic peptides, including B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP), identifies people at risk for heart failure development, progression of symptoms, and heart failure–related mortality (212–214).”
What the sources say
- Partly supportedcites [212] Januzzi, 2020, Effects of canagliflozin on amino-terminal pro-B-type natriuretic peptide: implications for cardiovascular risk reduction, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
The Discussion reports that elevated NT-proBNP is associated with incident heart failure in people with type 2 diabetes, and the results find baseline NT-proBNP prognostic for heart-failure hospitalization. The paper does not establish symptom progression or heart-failure-specific mortality as outcomes predicted by these measurements; it reports cardiovascular-death composites and all-cause death instead. The evidence presented concerns NT-proBNP, not a separate BNP measurement. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [213] Jarolim, 2018, Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE trial, Diabetes Care source
- Partly supportedcites [214] Pandey, 2021, Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes, JACC Heart Fail sourceExperimental — accuracy not yet measured
The Methods include NT-proBNP in a four-marker score, and the Results report that the score predicts incident heart failure in participants with diabetes and pre-diabetes. The paper does not establish the claim for BNP or for progression of symptoms and heart failure-related mortality; its stated outcome is incident heart failure. (LLM, conf=0.90)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Lixisenatide and extended-release exenatide were not superior to placebo with respect to the primary end point of cardiovascular outcomes (260) and therefore are not recommended for CVD risk reduction.”
What the sources say
- Supportedcites [260] Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med source
The Discussion reports that extended-release exenatide was not superior to placebo for cardiovascular efficacy. It also reports that the lixisenatide ELIXA trial found no significant difference from placebo in a cardiovascular composite outcome. The recommendation about CVD risk reduction is the citing authors’ conclusion, not part of the result attributed to this source. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Finally, in the Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED) trial, randomization to the SGLT1/2 inhibitor sotagliflozin reduced the primary outcome of death from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in people with type 2”
What the sources say
- Supportedcites [283] Bhatt, 2021, Sotagliflozin in patients with diabetes and chronic kidney disease, N Engl J Med source
The Methods (p. 2) identify the SCORED population as patients with type 2 diabetes, chronic kidney disease, and cardiovascular risk, and define the composite primary end point. The Results (p. 2) report fewer primary end-point events with sotagliflozin than placebo (5.6 vs. 7.5 per 100 patient-years; hazard ratio, 0.74). The claim concerns the composite outcome, not a significant reduction in each component individually. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SGLT2 inhibitors and GLP-1RA also reduce risk of heart failure hospitalization and progression of kidney disease in people with established ASCVD, multiple risk factors for ASCVD, or albuminuric kidney disease (264,265).”
What the sources say
- Not checked — no full text of the sourcecites [264] Zelniker, 2019, SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, Lancet source
- Partly supportedcites [265] McGuire, 2021, Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis, JAMA Cardiol sourceExperimental — accuracy not yet measured
The Results (page unavailable) report reduced hospitalization for heart failure and kidney-disease progression with SGLT2 inhibitors, including in analyses by ASCVD status and baseline albuminuria. This paper evaluates SGLT2 inhibitors, not GLP-1 receptor agonists, so it does not support the claim about both drug classes. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Subsequent retrospective analyses from both trials revealed that concomitant use of β-blockers was associated with decreased risk of progression to symptomatic heart failure (277,278).”
What the sources say
- Supportedcites [277] Exner, 1999, Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction, J Am Coll Cardiol source
The Survival curves section reports that SOLVD Prevention trial participants receiving both β-blockers and enalapril had significantly less progression to symptomatic heart failure, assessed by death or hospitalization for heart failure. This supports the SOLVD portion of the sentence; the separately cited SAVE analysis is not attributed to this source. Our copy does not provide a page number for the passage. (LLM, conf=0.90)
- Supportedcites [278] Vantrimpont, 1997, Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. SAVE Investigators, J Am Coll Cardiol source
For the SAVE portion of the cited sentence, the Results (section 2.2) associate β-blocker use with less severe heart failure, and the Discussion (section 3.1) reports a 21% lower risk. The Methods (section 1.2) define this outcome as heart failure requiring hospital admission or clinical deterioration requiring treatment. The authors caution that this retrospective association does not establish that β-blockers caused the reduction. (LLM, conf=0.91)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“For example, in the UK Prospective Diabetes Study (UKPDS) trial, intensive blood pressure management in people with type 2 diabetes reduced the risk for heart failure by 56% (273).”
What the sources say
- Supportedcites [273] UK Prospective Diabetes Study Group, 1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ source
The Discussion reports a 56% reduction in heart-failure risk among patients with hypertension and type 2 diabetes assigned to tight blood-pressure control. This directly supports the claim about the UKPDS trial. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A recently published meta-analysis of GLP-1 RA registration trials, including those for the commonly used medications dulaglutide, liraglutide, and semaglutide (both subcutaneous and oral), demonstrated a 14% relative reduction in the risk of hospitalization for heart failure (HR 0.86, 95% CI 0.79–0.93) (255).”
What the sources say
- Supportedcites [255] Lee, 2025, Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials, Diabetes Care source
The Results report that long-acting GLP-1 receptor agonists reduced hospitalization for heart failure by 14% compared with placebo, with the exact hazard ratio and confidence interval cited. The finding comes from a meta-analysis of trials in people with type 2 diabetes. (LLM, conf=0.94)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76–0.98]; P = 0.03) in people with type 2 diabetes and CKD (240).”
What the sources say
- Supportedcites [240] Pitt, 2021, Cardiovascular events with finerenone in kidney disease and type 2 diabetes, N Engl J Med source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A prespecified secondary outcome was death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure, which was reduced by 13% in the finerenone group.”
What the sources say
- Partly supportedcites [285] Bakris, 2020, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Outcomes section defines the prespecified key secondary composite as stated, and Primary and Key Secondary Outcomes reports fewer events with finerenone than placebo. The reported hazard ratio is 0.86, corresponding to a 14% lower hazard, not a 13% reduction; 13.0% is the proportion of finerenone patients who had an event. No page number is available in our copy. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intensive treatment of hypertension in people with diabetes in the BPROAD trial led to a 34% reduction in treatment or hospitalization for heart failure (HR 0.66, 95% CI 0.41–1.04), a finding that parallels observations from the SPRINT trial where the risk for development of incident heart failure decreased by 36% (42,274).”
What the sources say
- Not checked — no full text of the sourcecites [42] Bi, 2025, Intensive blood-pressure control in patients with type 2 diabetes, N Engl J Med source
- Partly supportedcites [274] Upadhya, 2017, Effect of intensive blood pressure treatment on heart failure events in the systolic blood pressure reduction intervention trial, Circ Heart Fail sourceExperimental — accuracy not yet measured
The Conclusions report a 36% reduction in acute decompensated heart failure (ADHF) with intensive blood-pressure treatment in SPRINT. The Discussion says new outpatient heart failure was not counted, so the result does not establish a 36% reduction in incident heart failure overall. (LLM, conf=0.87)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Intensive treatment of hypertension in people with diabetes in the BPROAD trial led to a 34% reduction in treatment or hospitalization for heart failure (HR 0.66, 95% CI 0.41–1.04), a finding that parallels observations from the SPRINT trial where the risk for development of incident heart failure decreased by 36% (42,274).”
What the sources say
- Not checked — no full text of the sourcecites [42] Bi, 2025, Intensive blood-pressure control in patients with type 2 diabetes, N Engl J Med source
- Supportedcites [274] Upadhya, 2017, Effect of intensive blood pressure treatment on heart failure events in the systolic blood pressure reduction intervention trial, Circ Heart Fail source
The citation supports the SPRINT comparison in the citing sentence, not the preceding BPROAD result. The paper’s Conclusions (page unavailable) state that intensive blood-pressure treatment reduced the risk of developing acute decompensated heart failure by 36% in SPRINT. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56–0.90]).”
What the sources say
- Supportedcites [240] Pitt, 2021, Cardiovascular events with finerenone in kidney disease and type 2 diabetes, N Engl J Med source
The paper identifies the trial as FIGARO-DKD. In “Effects on Primary Composite Outcome and Components,” it reports fewer heart-failure hospitalizations with finerenone than placebo and gives the claimed hazard ratio and confidence interval. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Meta-analyses of the trials reported to date suggest that GLP-1 RAs and SGLT2 inhibitors reduce risk of atherosclerotic major adverse cardiovascular events to a comparable degree in people with type 2 diabetes and established ASCVD (262,263).”
What the sources say
- Not checked — no full text of the sourcecites [262] Zelniker, 2019, Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus, Circulation source
- Partly supportedcites [263] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports that both drug classes reduced non-fatal myocardial infarction, with no detected difference between them. It also reports that GLP-1 receptor agonists reduced non-fatal stroke whereas SGLT-2 inhibitors had little or no effect. The paper does not report a comparable reduction in a composite of atherosclerotic major adverse cardiovascular events specifically among people with established ASCVD. (LLM, conf=0.88)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The incidence of heart failure hospitalization occurred less in the finerenone-treated group, and only 7.7% of study participants had a prior history of heart failure.”
What the sources say
- Supportedcites [285] Bakris, 2020, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes, N Engl J Med source
The Primary and Key Secondary Outcomes section (page not supplied) states that hospitalization for heart failure was among the outcome components with a lower incidence in the finerenone group than in the placebo group. This supports the quoted claim; it does not establish that the difference for this component alone was statistically significant. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Emerging data suggest that use of both classes of drugs will provide an additive cardiovascular and kidney outcomes benefit; thus, combination therapy with an SGLT2 inhibitor and a GLP-1 RA may be considered to provide the complementary outcomes benefits associated with these classes of medication (254), which are largely independent of glycemic management.”
What the sources say
- Supportedcites [254] Gerstein, 2021, Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes, N Engl J Med source
The Discussion (p. 7) reports lower cardiovascular and composite renal event risks with efpeglenatide and says these benefits appeared independent of baseline SGLT2-inhibitor use. It also suggests that efpeglenatide’s cardiovascular effects may be independent of an SGLT2 inhibitor’s effects. This supports the citing sentence’s cautious suggestion of added benefit from using both classes, rather than proving additivity conclusively. (LLM, conf=0.85)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An oral formulation of semaglutide has also demonstrated cardiovascular benefit (257–259).”
What the sources say
- Supportedcites [257] Marx, 2025, Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial, Circulation source
The Results report that, in the SOUL trial population, oral semaglutide lowered the risk of major adverse cardiovascular events by 14% versus placebo. The Discussion likewise describes beneficial cardiovascular effects in people with type 2 diabetes and established cardiovascular or chronic kidney disease. (LLM, conf=0.94)
- Supportedcites [258] Rebelo, 2025, Effects of oral semaglutide on cardiovascular outcomes: a systematic review and meta-analysis, Int J Cardiol source
Section 3.2, Cardiovascular Outcomes, reports a statistically significant reduction in cardiovascular outcomes with oral semaglutide across five studies. The benefit concerns composite cardiovascular outcomes in patients with type 2 diabetes; the paper does not find significant reductions in every individual outcome. (LLM, conf=0.92)
- Partly supportedcites [259] McGuire, 2023, Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial, Diabetes Obes Metab sourceExperimental — accuracy not yet measured
The Introduction reports that PIONEER 6 found a significant reduction in cardiovascular death with oral semaglutide versus placebo. It also says the trial demonstrated cardiovascular safety but was not powered to formally assess cardiovascular efficacy, so the unqualified claim of demonstrated cardiovascular benefit overstates what this source establishes. (LLM, conf=0.86)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Early primary prevention strategies and treatment of associated risk factors reduce incident, symptomatic heart failure and should include lifestyle intervention with nutrition, physical activity, weight management, and smoking cessation (268–271) (Fig. 10.5).”
What the sources say
- Partly supportedcites [268] Del Gobbo, 2015, Contribution of major lifestyle risk factors for incident heart failure in older adults: the Cardiovascular Health Study, JACC Heart Fail sourceExperimental — accuracy not yet measured
The Conclusions (page unavailable) report that physical activity, not smoking, and avoiding obesity were associated with lower incident heart-failure risk in older adults. The Methods confirm that cases had symptoms, but this observational study did not test whether early prevention or treatment of risk factors reduces heart failure. It also found no association between overall dietary patterns and lower heart-failure risk. (LLM, conf=0.88)
- Partly supportedcites [269] Young, 2014, Effects of physical activity and sedentary time on the risk of heart failure, Circ Heart Fail sourceExperimental — accuracy not yet measured
The Results and Clinical Perspective report that lower physical activity was associated with higher incidence of heart failure in a cohort of middle-aged and older men. The paper does not establish that early prevention strategies or treatment of associated risk factors reduce symptomatic heart failure; it says whether changing these behaviors affects risk remains for future study. (LLM, conf=0.86)
- Partly supportedcites [270] Tektonidis, 2016, Adherence to a Mediterranean diet is associated with reduced risk of heart failure in men, Eur J Heart Fail sourceExperimental — accuracy not yet measured
The Discussion (page unavailable in our copy) reports that greater adherence to a Mediterranean diet was associated with lower risk of developing heart failure in men, supporting the nutrition aspect of primary prevention. It does not establish that early interventions or treatment of risk factors reduce symptomatic heart failure, and it does not test physical activity, weight management, or smoking cessation as interventions. The observational association also does not establish the causal reduction asserted in the claim. (LLM, conf=0.88)
- Partly supportedcites [271] Levitan, 2009, Consistency with the DASH diet and incidence of heart failure, Arch Intern Med sourceExperimental — accuracy not yet measured
The Introduction discusses preventing heart failure through treatment and lifestyle measures targeting risk factors, and the Abstract Conclusions report that diets consistent with DASH were associated with lower heart-failure rates. But this observational finding does not establish that prevention strategies or risk-factor treatment reduce symptomatic heart failure; the paper also does not test physical activity, weight management, or smoking cessation as interventions. The Comment notes that its outcome captures heart failure resulting in hospitalization or death. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similar results were obtained in clinical trials with empagliflozin (291).”
What the sources say
- Supportedcites [291] Packer, 2020, Cardiovascular and renal outcomes with empagliflozin in heart failure, N Engl J Med source
The Discussion compares the empagliflozin trial directly with DAPA-HF and says that, in both trials, the benefit on the primary composite outcome was driven mainly by fewer heart-failure hospitalizations. It also notes differences in the trial populations and cardiovascular-death estimates, so “similar results” is supported as a broad comparison, not as identical effects. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A large meta-analysis (297) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality.”
What the sources say
- Supportedcites [297] Vaduganathan, 2022, SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials, Lancet source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
boosteddirectn = 21,947- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (290).”
What the sources say
- Supportedcites [290] Solomon, 2022, Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction, N Engl J Med source
The Discussion reports that dapagliflozin lowered the risk of worsening heart failure or cardiovascular death versus placebo in patients with mildly reduced or preserved ejection fraction. It also says the DELIVER results extend the benefit seen in the earlier DAPA-HF trial, supporting the comparison implied by “similar benefit.” (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition to the hospitalization and mortality benefit in people with heart failure, SGLT2 inhibitors improve clinical stability and functional status in individuals with heart failure (289,292–294).”
What the sources say
- Partly supportedcites [289] Nassif, 2021, The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial, Nat Med sourceExperimental — accuracy not yet measured
The Results (Patients section; page unavailable) report improved symptoms and physical limitations after 12 weeks of dapagliflozin in patients with HFpEF, supporting the functional-status part of the claim. The Trial design section says clinical stability was ensured before randomization; it does not report improved clinical stability as a treatment outcome. The trial's finding is also narrower than the claim's reference to SGLT2 inhibitors in people with heart failure generally. (LLM, conf=0.86)
- Partly supportedcites [292] Packer, 2021, Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial, Circulation sourceExperimental — accuracy not yet measured
The Results report that empagliflozin reduced worsening heart-failure events and increased the odds of improvement in NYHA functional class. The study concerns patients with reduced ejection fraction, so this source alone does not establish the claim for heart failure more broadly. (LLM, conf=0.85)
- Partly supportedcites [293] Voors, 2022, The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial, Nat Med sourceExperimental — accuracy not yet measured
The Results (Primary and secondary outcomes; page not provided) report fewer heart-failure events and a greater improvement in symptom scores with empagliflozin than with placebo. These findings support a clinical benefit, but the paper does not establish improved functional status as a separate outcome; its trial was limited to empagliflozin in patients hospitalized for acute heart failure, rather than SGLT2 inhibitors in all individuals with heart failure. (LLM, conf=0.84)
- Partly supportedcites [294] Spertus, 2022, The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial, Nat Med sourceExperimental — accuracy not yet measured
The Discussion reports that SGLT2 inhibitors improve symptoms, function and quality of life in people with heart failure, supporting the functional-status part of the claim. The Results > Outcomes report fewer patients with moderate or greater symptom-score deterioration on canagliflozin, but the paper does not establish improved clinical stability as a distinct outcome; the Discussion says the trial was not designed or powered to examine clinical events. No page numbers are available in our copy. (LLM, conf=0.79)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, three other cardiovascular outcomes trials—Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (312), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (313), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (314)—did not find a significant increase in risk of heart failure hospitalization with D”
What the sources say
- Not checked — no full text of the sourcecites [312] Zannad, 2015, Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet source
- Supportedcites [313] Green, 2015, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes, N Engl J Med source
The citation to this paper identifies TECOS, so the relevant part of the sentence is the TECOS finding. The Discussion (p. 8) reports no difference in heart-failure hospitalization between the sitagliptin and placebo groups (hazard ratio, 1.00). This paper does not need to establish the separately cited CARMELINA result. (LLM, conf=0.94)
- Supportedcites [314] Rosenstock, 2019, Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial, JAMA source
The CARMELINA paper’s Exploratory CV Analyses report no significant difference in heart-failure hospitalization between linagliptin and placebo (HR 0.90; 95% CI 0.74–1.08; P = .26). This supports the part of the sentence attributed to CARMELINA; the other trials have separate citations. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“in The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) study, participants randomized to saxagliptin were more likely to be hospitalized for heart failure than those given placebo (311).”
What the sources say
- Supportedcites [311] Scirica, 2013, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N Engl J Med source
The Discussion reports a higher incidence of hospitalization for heart failure among patients treated with saxagliptin and states that saxagliptin increased this risk. It cautions that the finding was unexpected and merits confirmation; the citing sentence accurately describes the observed comparison without claiming a class effect. (LLM, conf=0.94)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, in the confirmatory secondary end point, semaglutide treatment improved 6-min walk distance.”
What the sources say
- Supportedcites [306] Kosiborod, 2024, Semaglutide in patients with obesity-related heart failure and type 2 diabetes, N Engl J Med source
The Abstract reports that 6-minute walk distance was a confirmatory secondary endpoint and that its change favored semaglutide over placebo by an estimated 14.3 m (P=0.008) in STEP-HFpEF DM. (LLM, conf=0.94)
plaindirectn = 616- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the enrolled participants, 41% had type 2 diabetes.”
What the sources say
- Supportedcites [303] Solomon, 2024, Finerenone in heart failure with mildly reduced or preserved ejection fraction, N Engl J Med source
Table 1 in the Discussion lists type 2 diabetes in 1,217 of 3,003 finerenone participants and 1,222 of 2,998 placebo participants. Together, that is 2,439 of 6,001 participants, or 40.6%, which rounds to 41%. No page number is supplied in our copy. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial, sotagliflozin, a combined SGLT1/2 inhibitor, initiated during or shortly after hospitalization for heart failure in people with diabetes, also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits”
What the sources say
- Supportedcites [296] Bhatt, 2021, Sotagliflozin in patients with diabetes and recent worsening heart failure, N Engl J Med source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of dapagliflozin on the primary outcome was consistent regardless of the presence or absence of type 2 diabetes (287).”
What the sources say
- Supportedcites [287] McMurray, 2019, Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med source
The Outcomes section (p. 6) says the effect on the primary outcome was generally consistent across prespecified subgroups, including patients without diabetes at baseline. The Discussion (p. 8) states that dapagliflozin was as effective in patients without type 2 diabetes as in those with diabetes. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Increasing evidence has demonstrated the benefits of GLP-1 RA or dual GIP/GLP-1 RA on symptoms and outcomes for people with HFpEF and obesity, and while most people with HFpEF have obesity, approximately 45% have diabetes (304,305).”
What the sources say
- Not checked — no full text of the sourcecites [304] Echouffo-Tcheugui, 2016, Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry, Am Heart J source
- Could not verifycites [305] Haass, 2011, Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial, Circ Heart Fail sourceExperimental — accuracy not yet measured
The Methods describe a BMI analysis of patients in the I-PRESERVE irbesartan trial, and the Discussion reports associations between BMI and cardiovascular outcomes. Searches for GLP-1, GIP/GLP-1, semaglutide, and tirzepatide found no passage addressing whether those treatments benefit symptoms or outcomes in people with HFpEF and obesity. Page numbers are not available in our copy. (LLM, conf=0.76)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Increasing evidence has demonstrated the benefits of GLP-1 RA or dual GIP/GLP-1 RA on symptoms and outcomes for people with HFpEF and obesity, and while most people with HFpEF have obesity, approximately 45% have diabetes (304,305).”
What the sources say
- Not checked — no full text of the sourcecites [304] Echouffo-Tcheugui, 2016, Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry, Am Heart J source
- Could not verifycites [305] Haass, 2011, Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial, Circ Heart Fail sourceExperimental — accuracy not yet measured
The Discussion’s Clinical and Demographic Characteristics section says diabetes was less common in the lowest-BMI group, but gives no overall diabetes prevalence. I searched for 45%, diabetes prevalence, and the baseline characteristics in Table 1; the passages retrieved from our copy do not establish the claimed figure. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Initial treatment for hypertension should include any of the drug classes demonstrated to reduce cardiovascular events in people with diabetes (27): ACE inhibitors (62), angiotensin receptor blockers (ARBs) (62), thiazide-like diuretics (63), or dihydropyridine calcium channel blockers (64).”
What the sources say
- Not checked — no full text of the sourcecites [27] Mancia, 2023, 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA), J Hypertens source
- Not checked — no full text of the sourcecites [62] Ichikawa, 2025, Efficacy of renin-angiotensin system inhibitors, calcium channel blockers, and diuretics in hypertensive patients with diabetes: subgroup analysis based on albuminuria in a systematic review and meta-analysis, Hypertens Res source
- Not checked — no full text of the sourcecites [63] Barzilay, 2004, Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study, J Clin Hypertens (Greenwich) source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“BPROAD provides the strongest evidence to support a systolic blood pressure treatment goal of <120 mmHg, as it enrolled people with type 2 diabetes and increased cardiovascular risk with a baseline systolic blood pressure ≥140 mmHg (or 130–180 mmHg if already taking antihypertensive medication).”
What the sources say
- Not checked — no full text of the sourcecites [42] Bi, 2025, Intensive blood-pressure control in patients with type 2 diabetes, N Engl J Med source
boosteddirectn = 12,821- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Elevations in serum creatinine (up to 30% from baseline) with ACE inhibitors or ARBs must not be confused with AKI (79).”
What the sources say
- Not checked — no full text of the sourcecites [79] Bakris, 2000, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?, Arch Intern Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The results of BPROAD and ESPRIT highlight that targeting an on-treatment systolic blood pressure goal of <120 mmHg in people with high cardiovascular risk is associated with reduction in cardiovascular events compared with systolic blood pressure <140 mmHg.”
What the sources say
- Not checked — no full text of the sourcecites [42] Bi, 2025, Intensive blood-pressure control in patients with type 2 diabetes, N Engl J Med source
- Not checked — no full text of the sourcecites [43] Liu, 2024, Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial, Lancet source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The primary end point, a composite of cardiovascular death, nonfatal stroke or MI, or new or worsening kidney or eye disease, was reduced by 9% in the combination treatment.”
What the sources say
- Not checked — no full text of the sourcecites [46] Patel, 2007, Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial, Lancet source
plaindirectn = 11,140- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The investigators reported a modest increase in adverse events, including syncope (0.4% vs. 0.1%, HR 3.00, 95% CI 1.35–6.68) (43).”
What the sources say
- Not checked — no full text of the sourcecites [43] Liu, 2024, Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“However, in people with diabetes, there was a significant 51% reduction in MI, stroke, and cardiovascular death in the treatment group with a goal diastolic blood pressure of <80 mmHg compared with a goal diastolic blood pressure of <90 mmHg.”
What the sources say
- Not checked — no full text of the sourcecites [47] Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“the primary composite outcome of stroke, acute coronary syndrome, acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death from cardiovascular causes occurred in 3.5% of individuals in the intensive treatment group versus 4.6% in the standard treatment group (HR 0.74 [95% CI 0.60–0.92]; P = 0.007).”
What the sources say
- Not checked — no full text of the sourcecites [40] Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The Cholesterol Treatment Trialists’ Collaboration, involving 26 statin trials, of which 5 compared high-intensity versus moderate-intensity statins, showed a 21% reduction in major cardiovascular events in people with diabetes for every 39 mg/dL (1 mmol/L) of LDL cholesterol lowering, irrespective of baseline LDL cholesterol or individual characteristics (101).”
What the sources say
- Not checked — no full text of the sourcecites [101] Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“However, heterogeneity by age has not been seen in the relative benefit of lipid-lowering therapy in trials that included older participants (100,101,104), and because older age confers higher risk, the absolute benefits are actually greater (104,112).”
What the sources say
- Not checked — no full text of the sourcecites [100] Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet source
- Not checked — no full text of the sourcecites [101] Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet source
- Not checked — no full text of the sourcecites [104] Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Since cardiovascular risk is enhanced in people with diabetes, as noted above, individuals who also have multiple other coronary risk factors have increased risk, equivalent to that of those with ASCVD.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In the Heart Protection Study (lower age limit 40 years), the subgroup of ∼600 people with type 1 diabetes had a reduction in risk proportionately similar, although not statistically significant, to that in people with type 2 diabetes (95).”
What the sources say
- Not checked — no full text of the sourcecites [95] Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet source
plaindirectn = 600- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“It is important to note that the effects of statin therapy do not differ based on sex (92).”
What the sources say
- Not checked — no full text of the sourcecites [92] Fulcher, 2015, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“There is evidence for benefit from even extremely low, less-than-daily statin doses (91).”
What the sources say
- Not checked — no full text of the sourcecites [91] Meek, 2012, Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study, Curr Med Res Opin source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“A subanalysis of participants with diabetes (27% of the 18,144 participants) showed a significant reduction of major adverse cardiovascular events with the combination treatment over moderate-intensity statin alone (116).”
What the sources say
- Not checked — no full text of the sourcecites [116] Giugliano, 2018, Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), Circulation source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The cardiovascular benefit in this large meta-analysis did not depend on baseline LDL cholesterol levels and was linearly related to the LDL cholesterol reduction without a low threshold beyond which there was no benefit observed (101).”
What the sources say
- Not checked — no full text of the sourcecites [101] Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet source
plainn = 18,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The relative benefit of lipid-lowering therapy has been uniform across most subgroups tested (101,104), including subgroups that varied with respect to age and other risk factors.”
What the sources say
- Not checked — no full text of the sourcecites [101] Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet source
- Not checked — no full text of the sourcecites [104] Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Meta-analyses including data from >18,000 people with diabetes from 14 randomized trials of statin therapy (mean follow-up 4.3 years) demonstrated a 9% proportional reduction in all-cause mortality and 13% reduction in vascular mortality for each 1 mmol/L (39 mg/dL) reduction in LDL cholesterol (101).”
What the sources say
- Not checked — no full text of the sourcecites [101] Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet source
boostedcorrelationaln = 18,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Meta-analyses including data from >18,000 people with diabetes from 14 randomized trials of statin therapy (mean follow-up 4.3 years) demonstrated a 9% proportional reduction in all-cause mortality and 13% reduction in vascular mortality for each 1 mmol/L (39 mg/dL) reduction in LDL cholesterol (101).”
What the sources say
- Not checked — no full text of the sourcecites [101] Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet source
boostedcorrelationaln = 18,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The composite of cardiovascular death, nonfatal MI, or nonfatal stroke was reduced by 26% (P < 0.001).”
What the sources say
- Not matchedcites REDUCE-IT
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) showed that the addition of icosapent ethyl to statin therapy in this population resulted in a 25% relative risk reduction (P < 0.001) for the primary end point composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina compared with placebo.”
What the sources say
- Not matchedcites REDUCE-IT
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Additional ischemic end points were significantly lower in the icosapent ethyl group than in the placebo group, including cardiovascular death, which was reduced by 20% (P = 0.03).”
What the sources say
- Not matchedcites REDUCE-IT
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Statin therapy is a cornerstone of CVD prevention and treatment; however, a subset of individuals experience partial (inability to tolerate sufficient dosage necessary to achieve therapeutic objectives due to adverse effects) or complete (inability to tolerate any dose) intolerance to statin therapy (127).”
What the sources say
- Not checked — no full text of the sourcecites [127] Cheeley, 2022, NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient, J Clin Lipidol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“This risk reduction was seen in individuals with or without diabetes at baseline.”
What the sources say
- Not matchedcites REDUCE-IT
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“The proportions of individuals experiencing adverse events and serious adverse events were similar between the active and placebo treatment groups.”
What the sources say
- Not matchedcites REDUCE-IT
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“However, the evidence for the use of drugs that target these lipid fractions is substantially less robust than that for statin therapy (149).”
What the sources say
- Not checked — no full text of the sourcecites [149] Singh, 2007, High-density lipoprotein as a therapeutic target: a systematic review, JAMA source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Therefore, a concern that statins or other lipid-lowering agents might cause cognitive dysfunction or dementia is not currently supported by evidence and should not deter their use in individuals with diabetes at high risk for ASCVD (167).”
What the sources say
- Not checked — no full text of the sourcecites [167] Adhikari, 2021, Association between statin use and cognitive function: a systematic review of randomized clinical trials and observational studies, J Clin Lipidol source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Current evidence from randomized trials does not support cardiovascular risk reduction for other n-3 fatty acids, and results of the REDUCE-IT trial should not be extrapolated to other products (147).”
What the sources say
- Not checked — no full text of the sourcecites [147] Bhatt, 2019, Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The excess risk may be as high as 5 per 1,000 per year in real-world settings.”
What the sources say
- Not checked — no full text of the sourcecites [176] Pignone, 2006, Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis, Ann Intern Med source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“For people with documented ASCVD, use of aspirin for secondary prevention has far greater benefit than risk; for this indication, aspirin is still recommended (168).”
What the sources say
- Not checked — no full text of the sourcecites [168] Perk, 2012, European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts), Eur Heart J source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“However, a higher incidence of major bleeding, including intracranial hemorrhage, was noted with dual antiplatelet therapy.”
What the sources say
- Not checked — no full text of the sourcecites [190] Bhatt, 2019, Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Similarly, the addition of ticagrelor to aspirin reduced the risk of ischemic cardiovascular events compared with aspirin alone in people with diabetes and stable coronary artery disease (189,190).”
What the sources say
- Not checked — no full text of the sourcecites [189] Steg, 2019, Ticagrelor in patients with stable coronary disease and diabetes, N Engl J Med source
- Not checked — no full text of the sourcecites [190] Bhatt, 2019, Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In people with diabetes and prior MI (1–3 years before), adding ticagrelor to aspirin significantly reduces the risk of recurrent ischemic events, including cardiovascular and CHD death (188).”
What the sources say
- Not checked — no full text of the sourcecites [188] Bhatt, 2016, Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54, J Am Coll Cardiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Any benefit of noninvasive coronary artery disease screening methods, such as computed tomography calcium scoring, to identify subgroups for different treatment strategies remains unproven in asymptomatic people with diabetes, though research is ongoing.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The main adverse effect is an increased risk of gastrointestinal bleeding.”
What the sources say
- Not checked — no full text of the sourcecites [176] Pignone, 2006, Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis, Ann Intern Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Another randomized study showed that routine screening with coronary computed tomography angiography did not reduce the composite rate of all-cause mortality, nonfatal MI, or unstable angina in asymptomatic people with type 1 or type 2 diabetes (200).”
What the sources say
- Not checked — no full text of the sourcecites [200] Muhlestein, 2014, Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial, JAMA source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“A similar association and prognostic values of increased NT-proBNP with increased cardiovascular and all-cause mortality has been reported in people with type 1 diabetes (215).”
What the sources say
- Not checked — no full text of the sourcecites [215] Rørth, 2020, Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: the Thousand & 1 Study, Eur J Endocrinol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In the PAD Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) program, 30% of people aged 50–69 years with a history of cigarette smoking or diabetes, or aged ≥70 years regardless of risk factors, had PAD (223).”
What the sources say
- Not checked — no full text of the sourcecites [223] Hirsch, 2001, Peripheral arterial disease detection, awareness, and treatment in primary care, JAMA source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“or the initiation of GLP-1 RA, as recent clinical trial evidence supports a symptomatic benefit of GLP-1 RA in people with diabetes and PAD (235).”
What the sources say
- Not checked — no full text of the sourcecites [235] Bonaca, 2025, Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Clear cardiovascular benefits exist for ACE inhibitor or ARB therapy in people with diabetes.”
What the sources say
- Not checked — no full text of the sourcecites [237] Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med source
boosteddirectn = 9,297- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The Heart Outcomes Prevention Evaluation (HOPE) study randomized 9,297 individuals aged ≥55 years with a history of vascular disease or diabetes plus one other cardiovascular risk factor to either ramipril or placebo. Ramipril significantly reduced cardiovascular and all-cause mortality, MI, and stroke (237).”
What the sources say
- Not checked — no full text of the sourcecites [237] Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med source
plaindirectn = 9,297- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In the Survival and Ventricular Enlargement (SAVE) study, which enrolled asymptomatic people with reduced LVEF after MI, including 23% people with diabetes, treatment with captopril reduced the development of heart failure by 37% (276).”
What the sources say
- Not checked — no full text of the sourcecites [276] Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In addition, heart failure was a prespecified outcome of the randomized, placebo-controlled trial of semaglutide in people with type 2 diabetes and CKD and found a significant reduction in the risk of heart failure among those randomized to active semaglutide (284).”
What the sources say
- Not checked — no full text of the sourcecites [284] Pratley, 2024, Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial, J Am Coll Cardiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Individuals at even higher risk of heart failure, such as those with established ASCVD or CKD, are likely to see a larger absolute risk reduction than healthier individuals at relatively lower cardiovascular and kidney risk.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Finally, in the Reversal of Ventricular Remodeling With Toprol-XL (REVERT) trial, in which 45% of the people enrolled had diabetes, metoprolol improved adverse cardiac remodeling in asymptomatic individuals with an LVEF <40% and mild left ventricular dilatation (280).”
What the sources say
- Not checked — no full text of the sourcecites [280] Colucci, 2007, Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial, Circulation source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The vast majority of incident heart failure is preceded by hypertension; up to 91% of all new heart failure development in the Framingham cohort occurred in people with a previous diagnosis of hypertension (272).”
What the sources say
- Not checked — no full text of the sourcecites [272] Levy, 1996, The progression from hypertension to congestive heart failure, JAMA source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In the landmark Studies of Left Ventricular Dysfunction (SOLVD) study, in which 15% of people had diabetes, treatment with enalapril reduced incident heart failure in people with asymptomatic left ventricular dysfunction by 20% (275).”
What the sources say
- Not checked — no full text of the sourcecites [275] Yusuf, 1992, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In addition, the mean KCCQ-CSS improved significantly more in those on active tirzepatide (19.5) than in the placebo group (12.7) (307).”
What the sources say
- Not checked — no full text of the sourcecites [307] Packer, 2025, Tirzepatide for heart failure with preserved ejection fraction and obesity, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Worsening heart failure or cardiovascular death was less frequent in individuals receiving tirzepatide (9.9% of individuals) versus placebo (15.3% of individuals; HR 0.62, 95% CI 0.41–0.95).”
What the sources say
- Not checked — no full text of the sourcecites [307] Packer, 2025, Tirzepatide for heart failure with preserved ejection fraction and obesity, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Thiazolidinediones have a strong and consistent relationship with increased risk of heart failure (308,309) and should be avoided in people with heart failure.”
What the sources say
- Not checked — no full text of the sourcecites [308] Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet source
- Not checked — no full text of the sourcecites [309] Lincoff, 2007, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials, JAMA source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, finerenone improves cardiovascular and kidney outcomes in people with type 2 diabetes.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 66
- The quote only partly states this claim. 2
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“which is at least twofold more prevalent in people with diabetes compared with those without diabetes”
What the sources say
- Partly supportedcites [11] Kodama, 2020, Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis, ESC Heart Fail sourceExperimental — accuracy not yet measured
The Results section (Overall analysis of new-onset heart failure risk; page unavailable) reports a pooled risk ratio of 2.14 for new-onset heart failure in people with diabetes versus those without. That supports an approximately twofold higher risk, but the paper measures new-onset risk, not how prevalent heart failure is; its 95% confidence interval of 1.96–2.34 also does not establish 'at least twofold' throughout. (LLM, conf=0.87)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“only a minority of people with type 2 diabetes achieve recommended risk factor goals and are treated with guideline-recommended therapy (7–9).”
What the sources say
- Could not verifycites [7] Mohebi, 2022, Cardiovascular disease projections in the United States Based on the 2020 Census estimates, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
The Results section projects diabetes prevalence, while the Methods section defines diabetes for that analysis; neither reports how many people with type 2 diabetes meet risk-factor goals or receive guideline-recommended therapy. A search for those terms and related treatment-and-control language found no passage addressing the claim in our copy. Page numbers were not available for these passages. (LLM, conf=0.75)
- Partly supportedcites [8] Kazemian, 2019, Evaluation of the cascade of diabetes care in the United States, 2005-2016, JAMA Intern Med sourceExperimental — accuracy not yet measured
The Results and Discussion (pages not provided) report that only 23% of US adults with diagnosed diabetes met the combined glycemic, blood-pressure, cholesterol, and nonsmoking goal. The paper does not establish that only a minority received guideline-recommended therapy: it reports that six in ten took a statin, but does not measure receipt of all recommended therapies. Its population is adults with diagnosed diabetes, not specifically type 2 diabetes. (LLM, conf=0.85)
- Partly supportedcites [9] Nelson, 2022, Use of lipid-, blood pressure-, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease, JAMA Netw Open sourceExperimental — accuracy not yet measured
The Conclusions report that fewer than 1 in 20 patients received all three evidence-based cardiovascular risk–mitigating therapies, supporting the treatment portion of the claim. The study concerns patients with both type 2 diabetes and ASCVD, not all people with type 2 diabetes. Its Results list risk-factor measurements but do not report the proportion achieving recommended risk-factor goals. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Randomized clinical trials have demonstrated unequivocally that treatment of hypertension reduces cardiovascular events as well as microvascular complications (34–40).”
What the sources say
- Not checked — no full text of the sourcecites [34] Emdin, 2015, Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis, JAMA source
- Partly supportedcites [35] Arguedas, 2013, Blood pressure targets for hypertension in people with diabetes mellitus, Cochrane Database Syst Rev sourceExperimental — accuracy not yet measured
The trial description in Acknowledgements (page unavailable) says antihypertensive drug classes had been shown to reduce cardiovascular events in people with diabetes. But the Discussion (page unavailable) reports no significant benefit of intensive blood-pressure lowering over standard control for macrovascular or microvascular events. The review compares blood-pressure targets, not treatment against no treatment, so it does not establish the claimed unequivocal reduction in both types of complication. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [36] Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet source
- Partly supportedcites [37] Brunström, 2016, Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses, BMJ sourceExperimental — accuracy not yet measured
The Results (page unavailable) report fewer cardiovascular events with treatment in patients with diabetes at higher baseline systolic blood pressures, and fewer cases of end-stage renal disease only when baseline pressure exceeded 150 mm Hg. The unqualified claim overstates the evidence: below 140 mm Hg, further treatment was associated with increased cardiovascular mortality and no observed renal benefit. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [38] Bangalore, 2011, Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials, Circulation source
- Not checked — no full text of the sourcecites [39] Thomopoulos, 2017, Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials, J Hypertens source
- Not checked — no full text of the sourcecites [40] Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“large benefits are seen when multiple cardiovascular risk factors (glycemic, blood pressure, and lipid management) are addressed simultaneously, with evidence for long-lasting benefits (3–5).”
What the sources say
- Supportedcites [3] Gæde, 2016, Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial, Diabetologia source
The Introduction (page not available) identifies hyperglycaemia, hypertension and dyslipidaemia as risk factors and describes a multifactorial intervention in patients with type 2 diabetes and microalbuminuria. The Cardiovascular disease section reports substantially fewer events with intensive therapy, while the Discussion reports a survival advantage and longer time before a first cardiovascular event over long-term follow-up. The evidence is specific to the trial’s patient population. (LLM, conf=0.92)
- Supportedcites [4] Gaede, 2008, Effect of a multifactorial intervention on mortality in type 2 diabetes, N Engl J Med source
The Results report that intensive therapy improved glycemic, blood-pressure, and lipid measures compared with conventional therapy. Over 13.3 years, the intensive-therapy group had a 29% absolute reduction in cardiovascular-event risk, with no evidence that the benefit changed after the intervention ended (Results, section labeled 586). (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [5] Khunti, 2018, Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: time to overcome multifactorial therapeutic inertia?, Diabetes Obes Metab source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“the incidence of all three conditions rises with increasing A1C levels (19).”
What the sources say
- Supportedcites [19] Honigberg, 2021, Cardiovascular and kidney outcomes across the glycemic spectrum: insights from the UK Biobank, J Am Coll Cardiol source
The Results (Incident Disease Outcomes; page not provided) report a substantial gradient of risk for ASCVD, heart failure, and CKD across HbA1c levels. Risk for all three was higher at HbA1c ≥7.0% than at <5.0%, supporting the citing sentence's broad trend; the paper also notes that risk appeared to nadir around 5.0%, so it does not claim a strictly monotonic rise at every level. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“While the relatively underpowered ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial (ACCORD BP) did not demonstrate that aiming for a systolic blood pressure <120 mmHg in people with diabetes results in decreased cardiovascular event rates, the prespecified secondary outcome of stroke was reduced by 41% with intensive treatment (45).”
What the sources say
- Supportedcites [45] Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The primary composite outcome of nonfatal MI, nonfatal stroke, or death from cardiovascular causes was not significantly reduced in the intensive treatment group, although the prespecified secondary outcome of stroke was significantly reduced by 41% in the intensive treatment group.”
What the sources say
- Supportedcites [45] Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainn = 4,733- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Antihypertensive drugs known to be effective and safe in pregnancy include methyldopa, labetalol, and long-acting nifedipine, while hydralazine may be considered in the acute management of hypertension in pregnancy or severe preeclampsia (72).”
What the sources say
- Supportedcites [72] Garovic, 2022, Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association, Hypertension source
The Antihypertensive medications section identifies labetalol and methyldopa as accepted first-line treatments and says some societies also support nifedipine. It reports that parenteral hydralazine and oral nifedipine, including long-acting formulations, are among drugs studied for acute severe hypertension in pregnancy and were found comparable in safety and efficacy. The paper also notes limitations in the evidence on fetal safety. (LLM, conf=0.87)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The results of BPROAD and ESPRIT are supported by the Systolic Blood Pressure Intervention Trial (SPRINT), which demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (44).”
What the sources say
- Supportedcites [44] Wright, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med source
The Discussion reports a 25% lower relative risk of the primary cardiovascular outcome with a systolic blood-pressure target below 120 mm Hg versus below 140 mm Hg. It specifies that participants had hypertension without diabetes and describes the trial population as at high risk for cardiovascular events. (LLM, conf=0.94)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Treatment with ACE inhibitors and ARBs or MRAs can cause AKI and hyperkalemia, while diuretics can cause AKI and either hypokalemia or hyperkalemia (depending on mechanism of action) (77,78).”
What the sources say
- Partly supportedcites [77] Nilsson, 2017, Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system, Int J Cardiol sourceExperimental — accuracy not yet measured
The Discussion (p. 6) associates ACE inhibitors, ARBs, MRAs, and potassium-sparing diuretics with hyperkalemia risk, and identifies diuretics as a strong risk factor for hypokalemia. The paper does not establish that these treatments cause AKI. Its observational analysis also cautions that medication effects cannot be disentangled from comorbidities, so the causal wording goes beyond its findings. (LLM, conf=0.88)
- Partly supportedcites [78] Bandak, 2017, Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project, J Am Heart Assoc sourceExperimental — accuracy not yet measured
The Introduction and Results (Risk Factors for Hyperkalemia After ACE-I/ARB Initiation; pages not provided) support hyperkalemia as a risk with ACE inhibitors and ARBs and identify potassium-sparing diuretics as a risk factor during their use. The paper does not establish the claimed AKI risks, address MRAs specifically, or support the claim that diuretics can cause hypokalemia. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the absence of albuminuria, risk of progressive kidney disease is low, and ACE inhibitors and ARBs have not been found to afford superior cardioprotection compared with thiazide-like diuretics or dihydropyridine calcium channel blockers (69).”
What the sources say
- Partly supportedcites [69] Reinhart, 2023, First-line diuretics versus other classes of antihypertensive drugs for hypertension, Cochrane Database Syst Rev sourceExperimental — accuracy not yet measured
The Authors’ Conclusions (page unavailable) report no proven clinically important advantage of other drug classes over first-line thiazides, and the Discussion reports no clear cardiovascular advantage for ACE inhibitors or ARBs over diuretics. The review does not establish that progressive kidney disease risk is low without albuminuria, or compare ACE inhibitors and ARBs directly with dihydropyridine calcium channel blockers for cardioprotection. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, heterogeneity by age has not been seen in the relative benefit of lipid-lowering therapy in trials that included older participants (100,101,104), and because older age confers higher risk, the absolute benefits are actually greater (104,112).”
What the sources say
- Not checked — no full text of the sourcecites [104] Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet source
- Partly supportedcites [112] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med sourceExperimental — accuracy not yet measured
The Efficacy End Points section (page unavailable in our copy) says the benefit of adding ezetimibe appeared particularly pronounced in patients aged 75 or older. It does not establish that older age conferred higher baseline risk or that the greater benefit was specifically an absolute benefit caused by that risk. The trial also studied patients after acute coronary syndromes, rather than lipid-lowering therapy generally. (LLM, conf=0.82)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Use of low-dose statins was allowed in these studies and was associated with an increase in the incidence of musculoskeletal adverse effects (129,130).”
What the sources say
- Not checked — no full text of the sourcecites [129] Sullivan, 2012, Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial, JAMA source
- Supportedcites [130] Stroes, 2014, Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab, J Am Coll Cardiol source
The Methods section says GAUSS-2 enrolled patients taking no statin or a low-dose statin. The results passage under OTHER LIPIDS reports higher myalgia rates among low-dose statin users in both treatment groups, supporting the stated association with musculoskeletal adverse effects. (LLM, conf=0.92)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Individuals of childbearing potential are less likely to be treated with statins or achieve their LDL cholesterol goals based on their cardiovascular risk (138–140).”
What the sources say
- Not checked — no full text of the sourcecites [138] Agarwala, 2024, Dyslipidemia management in women of reproductive potential: an expert clinical consensus from the national lipid association, J Clin Lipidol source
- Partly supportedcites [139] Roeters van Lennep, 2023, Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society, Eur Heart J sourceExperimental — accuracy not yet measured
The “Call to action” section says women at high cardiovascular risk are less likely than men to be prescribed statins. The “Familial hypercholesterolaemia” section reports lower LDL-C goal attainment and interrupted statin treatment around pregnancy, but specifically for women with FH. The paper does not establish both outcomes for all individuals of childbearing potential according to cardiovascular risk. (LLM, conf=0.87)
- Partly supportedcites [140] Nanna, 2019, Sex differences in the use of statins in community practice, Circ Cardiovasc Qual Outcomes sourceExperimental — accuracy not yet measured
The Results (Statin Use and Dosing Intensity; page not provided) show that statin-eligible females were less likely than males to receive a statin or guideline-recommended intensity. The paper does not establish this specifically for individuals of childbearing potential or report whether they achieved LDL-cholesterol goals. (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“It is important to note that of the ORION-3 participants, 23% had diabetes and 33% were not taking statin therapy.”
What the sources say
- Supportedcites [133] Ray, 2023, Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial, Lancet Diabetes Endocrinol source
Table 1 in the Results reports diabetes mellitus in 87/372 participants (23%) and any statin therapy in 249/374 (67%), leaving 33% not taking statins. These percentages use the participants with data available for each characteristic, rather than all 382 enrolled participants. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Bempedoic acid, a newer LDL cholesterol–lowering agent targeting the same pathway as statins but without activity in skeletal muscle, thus limiting muscle-related adverse effects, lowers LDL cholesterol levels by 15% for those on statins and 24% for those not taking statins (134).”
What the sources say
- Partly supportedcites [134] De Filippo, 2023, Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials, Cardiovasc Diabetol sourceExperimental — accuracy not yet measured
The Results (page unavailable) report a 24.13% LDL-C reduction without background statin therapy and a 15.67% reduction with high-intensity statins. They report a 19.58% reduction with moderate- or low-intensity statins, so the citing sentence overgeneralizes the 15% figure to everyone taking statins. The Introduction also supports the description of bempedoic acid’s pathway and limited skeletal-muscle activity. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Reductions in LDL cholesterol ranged from 55% and 56% for evolocumab biweekly and monthly plus daily oral placebo, respectively, to 19% and 16% for ezetimibe daily plus biweekly or monthly subcutaneous placebo, respectively.”
What the sources say
- Not checked — no full text of the sourcecites [129] Sullivan, 2012, Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial, JAMA source
- Partly supportedcites [130] Stroes, 2014, Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
Table 2 (Efficacy Outcomes; page not supplied) supports the treatment comparisons and approximately 19% LDL-C reduction for the biweekly-placebo ezetimibe group. But it reports 56.1% for biweekly evolocumab and 55.3% for monthly evolocumab—the reverse of the cited sentence—and 16.6%, not 16%, for the monthly-placebo ezetimibe group. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fewer musculoskeletal adverse effects occurred in those treated with evolocumab or ezetimibe than in those treated with ezetimibe plus placebo, although rates of discontinuation due to these effects were similar.”
What the sources say
- Not checked — no full text of the sourcecites [129] Sullivan, 2012, Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial, JAMA source
- Partly supportedcites [130] Stroes, 2014, Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
The GAUSS-2 Results report fewer muscle adverse events with evolocumab than with ezetimibe (12% versus 23%) and similar discontinuation rates due to musculoskeletal effects (5% versus 6%). They do not support the claim that ezetimibe had fewer such effects than “ezetimibe plus placebo”: the ezetimibe group received placebo injections. This paper reports GAUSS-2, not OSLER. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the 27,564 participants in FOURIER, 197 (0.7%) had type 1 diabetes and 10,834 (39.3%) had type 2 diabetes.”
What the sources say
- Supportedcites [114] Kang, 2025, Cardiovascular outcomes and efficacy of the PCSK9 inhibitor evolocumab in individuals with type 1 diabetes: insights from the FOURIER trial, Diabetes Care source
The Results (Baseline Characteristics) give the FOURIER total as 27,564 participants and report 197 (0.7%) with type 1 diabetes and 10,834 (39.3%) with type 2 diabetes. These figures exactly match the citing sentence. (LLM, conf=0.95)
plainn = 27,564- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It is important to note that ∼19% of individuals were on very-low-dose statin therapy at baseline (135).”
What the sources say
- Partly supportedcites [135] Nissen, 2023, Bempedoic acid and cardiovascular outcomes in statin-intolerant patients, N Engl J Med sourceExperimental — accuracy not yet measured
The Trial Population section says patients taking a very low average daily statin dose could enroll. The Results report that 22.7% of participants were taking a statin at baseline, but do not establish that approximately 19% were taking a very-low-dose statin. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although the evidence is limited, statins did not increase teratogenic effects for individuals with familial hypercholesterolemia (141,142), and a meta-analysis of pravastatin in pregnant individuals showed a reduction in preeclampsia, premature birth, and neonatal intensive care unit admissions (143).”
What the sources say
- Supportedcites [143] Mészáros, 2022, Pravastatin in preeclampsia: a meta-analysis and systematic review, Front Med (Lausanne) source
The Abstract Results and Discussion §4.1 report lower rates of preeclampsia, preterm birth, and NICU admission in the pravastatin meta-analysis. The analysis concerned treatment started before 20 weeks of gestation in patients at high risk of preeclampsia; the paper describes the neonatal findings as promising rather than definitive. (LLM, conf=0.92)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There were similar rates of any adverse event for all treatments; however, fewer events that led to treatment discontinuation and few skeletal muscle–related adverse events occurred with alirocumab (128).”
What the sources say
- Supportedcites [128] Moriarty, 2015, Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial, J Clin Lipidol source
Table 3 (24-week safety results; page not provided) reports similar rates of any adverse event across the three arms: 82.5% with alirocumab, 80.6% with ezetimibe, and 85.7% with atorvastatin. Adverse events leading to discontinuation and skeletal muscle-related adverse events were less frequent with alirocumab than with either comparator. The Safety and tolerability section qualifies that the muscle-event difference was statistically significant versus atorvastatin, but not versus ezetimibe. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous randomized controlled trials of aspirin, specifically in people with diabetes, failed to consistently show a significant reduction in overall ASCVD end points, raising questions about the efficacy of aspirin for primary prevention in people with diabetes, although some sex differences were suggested (169–171).”
What the sources say
- Partly supportedcites [169] Belch, 2008, The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease, BMJ sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [170] Zhang, 2010, Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis, Diabetes Res Clin Pract source
- Supportedcites [171] De Berardis, 2009, Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials, BMJ source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In contrast, major bleeding was significantly increased from 3.2 to 4.1% in the aspirin group (rate ratio 1.29; P = 0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding.”
What the sources say
- Supportedcites [173] Bowman, 2018, Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med source
The Results (p. 1) report major bleeding in 4.1% of the aspirin group versus 3.2% of the placebo group (rate ratio 1.29; P = 0.003). The same passage states that most of the excess was gastrointestinal and other extracranial bleeding. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (156,157), which may be limited to those with diabetes risk factors and/or impaired glucose tolerance.”
What the sources say
- Supportedcites [156] Rajpathak, 2009, Statin therapy and risk of developing type 2 diabetes: a meta-analysis, Diabetes Care source
The Conclusions (page not supplied) report a small, statistically significant increase in incident diabetes in the meta-analysis of five hypothesis-testing trials, while noting that the increase was not significant when all available trials were included. They also suggest that statins may uncover diabetes in high-risk individuals and note that 77% of JUPITER statin recipients who developed diabetes had impaired fasting glucose at entry. This supports the citing sentence’s tentative wording, not a demonstrated restriction of risk to that group. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [157] Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There were no significant differences by sex, weight, or duration of diabetes or other baseline factors, including ASCVD risk score.”
What the sources say
- Supportedcites [173] Bowman, 2018, Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med source
The subgroup-results section (p. 6) reports no clear evidence that aspirin’s proportional effects on vascular events or major bleeding varied by baseline characteristics, including baseline vascular-risk group. The Discussion (p. 9) also says an anticipated difference by body weight was not confirmed. These were exploratory analyses, so the finding is an absence of significant variation, not proof that effects were identical. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the PROMINENT trial, in people with type 2 diabetes and elevated triglycerides (≥200 mg/dL and low HDL [≤40 mg/dL]), pemafibrate 0.2 mg twice daily reduced triglycerides by 26% but did not reduce the risk of the primary outcome of nonfatal MI, nonfatal stroke, hospitalization for unplanned coronary revascularization, or cardiovascular death (151).”
What the sources say
- Partly supportedcites [151] Das Pradhan, 2022, Triglyceride lowering with pemafibrate to reduce cardiovascular risk, N Engl J Med sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Neither the ACCORD-lipid trial nor the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) trial, both conducted in people with type 2 diabetes on statin therapy, found that the fibrate fenofibrate or pemafibrate improved cardiovascular outcomes (150,151).”
What the sources say
- Not checked — no full text of the sourcecites [150] Maki, 2016, Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia, J Clin Lipidol source
- Supportedcites [151] Das Pradhan, 2022, Triglyceride lowering with pemafibrate to reduce cardiovascular risk, N Engl J Med source
The Results (p. 2) report no reduction in cardiovascular events with pemafibrate in PROMINENT. The Discussion (p. 10) describes those neutral findings as consistent with the ACCORD trial of fenofibrate and says that, unlike FIELD, these trials involved patients receiving statins. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The largest reduction was for nonfatal MI, with little effect on CHD death (relative risk 0.95 [95% CI 0.78–1.15]) or total stroke.”
What the sources say
- Partly supportedcites [172] Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet sourceExperimental — accuracy not yet measured
The Results report that, in primary prevention trials, the reduction in coronary events came mainly from fewer nonfatal MIs, with no clear reduction in CHD mortality. They give the CHD-death estimate as RR 0.95 with a 99% CI of 0.78–1.15, not the claimed 95% CI. The Results also report no net effect on total stroke in primary prevention, but a significant reduction in total stroke in secondary prevention; the claim omits that distinction. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Two other large, randomized trials of aspirin for primary prevention, in people without diabetes (ARRIVE [Aspirin to Reduce Risk of Initial Vascular Events]) (174) and in the elderly (ASPREE [Aspirin in Reducing Events in the Elderly]) (175), in which 11% of participants had diabetes, found no benefit of aspirin on the primary efficacy end point and an increased risk of bleeding.”
What the sources say
- Supportedcites [174] Gaziano, 2018, Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial, Lancet source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [175] McNeil, 2018, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl J Med sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Coronary calcium scoring in asymptomatic people with diabetes may help in risk stratification (203,204) and provide reasoning for treatment intensification and/or guiding informed individual decision-making and willingness for medication initiation and participation.”
What the sources say
- Not checked — no full text of the sourcecites [203] Elkeles, 2008, Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study, Eur Heart J source
- Supportedcites [204] Malik, 2017, Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the multi-ethnic study of atherosclerosis, JAMA Cardiol source
The Discussion states that CAC scoring identifies lower- and higher-risk people with diabetes and improves risk classification beyond standard risk scores. The Conclusions suggest that using CAC to focus treatment intensity may improve personalization of preventive therapies; they do not claim that treatment intensification has been shown to reduce events. (LLM, conf=0.88)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Evidence supports use of either ticagrelor or clopidogrel if no percutaneous coronary intervention was performed and clopidogrel, ticagrelor, or prasugrel if a percutaneous coronary intervention was performed (187).”
What the sources say
- Supportedcites [187] Vandvik, 2012, Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest source
Section 3.2.1–3.2.5 recommends ticagrelor or clopidogrel for patients who have not undergone PCI, and ticagrelor, clopidogrel, or prasugrel for those who have undergone PCI with stent placement. The recommendations concern the first year after an acute coronary syndrome and specify that each drug is used with low-dose aspirin. (LLM, conf=0.92)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While there was an increased risk of lower-limb amputation with canagliflozin in one trial (247), no significant increase in lower-limb amputations, fractures, AKI, or hyperkalemia was seen in other trials of canagliflozin (248).”
What the sources say
- Supportedcites [247] Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med source
The Safety Outcomes section reports a higher risk of lower-limb amputation with canagliflozin than with placebo in the CANVAS program (6.3 vs. 3.4 per 1000 patient-years). This supports the first clause, to which this source is cited; the statement about other trials is attached to a different citation. (LLM, conf=0.91)
- Partly supportedcites [248] Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med sourceExperimental — accuracy not yet measured
The Effects on Safety Outcomes section reports no significant increase in lower-limb amputation or fracture in this canagliflozin trial. The Trial Procedures section also notes that increased amputation risk had been identified in another trial, though that part of the citing sentence is attached to a different citation. Our copy does not establish the claimed absence of significant increases in acute kidney injury or hyperkalemia; the hyperkalemia passage only defines how those events were reported. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Risk factors associated with an increased risk for PAD in people with diabetes include age, smoking, hypertension, dyslipidemia, worse glycemic management, longer duration of diabetes, neuropathy, and retinopathy as well as a prior history of CVD (226,227).”
What the sources say
- Supportedcites [226] Adler, 2002, UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes, Diabetes Care source
The Results in the Analytical methods section identify age, higher HbA1c and systolic blood pressure, lower HDL cholesterol, current smoking, and prior cardiovascular disease as independent risk factors for incident PVD. The same section reports univariate associations for neuropathy and retinopathy and increasing PVD prevalence with longer diabetes duration. The claim says these factors are associated with risk, not that each is an independent predictor. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [227] Al-Delaimy, 2004, Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men, Am J Med source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“People with type 2 diabetes and CKD should be considered for treatment with finerenone to reduce cardiovascular outcomes and the risk of CKD progression (239–242).”
What the sources say
- Partly supportedcites [239] Filippatos, 2022, Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial, Circulation sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports that finerenone lowered a composite cardiovascular outcome in patients with type 2 diabetes and CKD. This paper’s analyses focus on heart-failure and cardiovascular outcomes; the passages do not report that finerenone reduced CKD progression, so that part of the attributed claim is unsupported by this source. (LLM, conf=0.87)
- Partly supportedcites [240] Pitt, 2021, Cardiovascular events with finerenone in kidney disease and type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion reports fewer cardiovascular events with finerenone in the FIGARO-DKD trial. It also reports improved kidney outcomes in the earlier FIDELIO-DKD trial, but FIGARO-DKD did not find a statistically significant reduction in its main kidney composite outcome. The unqualified claim about reduced CKD progression therefore goes beyond this trial's primary kidney finding. (LLM, conf=0.85)
- Supportedcites [241] Agarwal, 2022, Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis, Eur Heart J source
The Discussion reports that, in a pooled analysis of patients with type 2 diabetes and CKD, finerenone reduced both the composite cardiovascular outcome and the composite kidney outcome compared with placebo. Its conclusion also states that finerenone reduced clinically important cardiovascular and kidney outcomes across the studied spectrum of CKD. (LLM, conf=0.94)
- Could not verifycites [242] Anker, 2021, Empagliflozin in heart failure with a preserved ejection fraction, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion reports cardiovascular benefits of empagliflozin in patients with heart failure and preserved ejection fraction. Searches for finerenone and CKD progression found no passage addressing finerenone’s effects in people with type 2 diabetes and CKD. (LLM, conf=0.77)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Similarly, in other screening studies, 26% of people with diabetes have been shown to have PAD (224), and diabetes increased the odds of having PAD by 85% (225).”
What the sources say
- Not checked — no full text of the sourcecites [224] Lange, 2004, High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes, Exp Clin Endocrinol Diabetes source
- Supportedcites [225] Grøndal, 2015, Baseline prevalence of abdominal aortic aneurysm, peripheral arterial disease and hypertension in men aged 65-74 years from a population screening study (VIVA trial), Br J Surg source
The citation to this paper is attached to the 85% higher odds of PAD, not the separate 26% prevalence claim. Table 1 (labeled Discussion in our copy) reports a PAD odds ratio of 1.85 for diabetes mellitus among screened men aged 65–74, matching that attributed result. (LLM, conf=0.92)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the CANVAS Program, hospitalization from heart failure was reduced by 33% in people allocated to canagliflozin, and only 14% of individuals enrolled had a prior history of heart failure (247).”
What the sources say
- Supportedcites [247] Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med source
The hospitalization-for-heart-failure figure reports a hazard ratio of 0.67 (95% CI, 0.52–0.87) for canagliflozin versus placebo, corresponding to a 33% lower hazard. Table 1 (Baseline Characteristics) reports a history of heart failure in 1461 of 10,142 participants (14.4%), consistent with the cited sentence’s rounded 14%. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the EMPA-REG OUTCOME trial, only 10% of study participants had a prior history of heart failure, and treatment with empagliflozin reduced the relative risk for hospitalization from heart failure by 35% (281).”
What the sources say
- Partly supportedcites [281] Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Results (p. 1) report a 35% relative risk reduction in hospitalization for heart failure with empagliflozin. The Study Patients section (p. 4) refers to baseline characteristics in a supplementary table, but the passages in our copy do not establish that only 10% had a prior history of heart failure. (LLM, conf=0.85)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the DECLARE-TIMI 58 study, only 10% of study participants had a prior history of heart failure, and dapagliflozin reduced cardiovascular mortality and hospitalization for heart failure by 17%, which was consistent across multiple study subgroups regardless of a prior history of heart failure (282).”
What the sources say
- Supportedcites [282] Wiviott, 2019, Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med source
The trial’s subgroup figure (Discussion; page not provided) shows that about 10% of participants had a history of heart failure and gives a hazard ratio of 0.83 for the composite outcome of cardiovascular death or heart-failure hospitalization—a 17% relative reduction. The Discussion says this benefit was consistent across multiple subgroups, including participants with and without prior heart failure. The 17% figure applies to the composite outcome, not to cardiovascular mortality separately. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin reduce the incidence of heart failure and improve heart failure–related outcomes, including hospitalization for heart failure and heart failure–related symptoms, in people with diabetes with preserved or reduced ejection fraction (242,247,248,281,286–294).”
What the sources say
- Partly supportedcites [242] Anker, 2021, Empagliflozin in heart failure with a preserved ejection fraction, N Engl J Med sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [247] Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The discussion reports a lower risk of hospitalization for heart failure with canagliflozin than with placebo in patients with type 2 diabetes, while cautioning that this finding was not considered statistically significant under the prespecified testing sequence (page not specified in our copy). The paper does not establish reduced incidence of heart failure, improved heart-failure symptoms, effects of dapagliflozin or empagliflozin, or outcomes by preserved versus reduced ejection fraction. (LLM, conf=0.88)
- Partly supportedcites [248] Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Dapagliflozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65–0.85]), lower risk of first worsening heart failure event (HR 0.70 [95% CI 0.59–0.83]), and lower risk of cardiovascular death (HR 0.82 [95% CI 0.69–0.98]) compared with placebo.”
What the sources say
- Supportedcites [287] McMurray, 2019, Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med source
The Results (p. 2) report all three comparisons with the cited hazard ratios and confidence intervals: the primary outcome, first worsening heart failure event, and cardiovascular death. The Methods (p. 2) identify the trial population as patients with NYHA class II–IV heart failure and an ejection fraction of 40% or less. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The findings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all five trials combined.”
What the sources say
- Supportedcites [297] Vaduganathan, 2022, SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials, Lancet source
The Results report no evidence of between-trial heterogeneity for the assessed outcomes, and the Discussion says the endpoint components were highly concordant between DELIVER and EMPEROR-Preserved. The paper also states that it found no statistical heterogeneity across all five trials for any endpoint. (LLM, conf=0.91)
plainn = 21,947- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved), the primary outcome of cardiovascular death or hospitalization for heart failure was reduced in adults with NYHA functional class I–IV and chronic HFpEF (LVEF >40%), extending the previously seen benefit in people with heart failure to those with preserved ejection fraction”
What the sources say
- Partly supportedcites [242] Anker, 2021, Empagliflozin in heart failure with a preserved ejection fraction, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion reports a lower risk of cardiovascular death or heart-failure hospitalization with empagliflozin, including in patients with or without diabetes. The Patients section specifies adults with LVEF greater than 40%, but its eligibility criterion was NYHA class II–IV, not I–IV. A table note mentions four class I patients; that does not make class I part of the stated eligibility criterion. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (296,298).”
What the sources say
- Partly supportedcites [296] Bhatt, 2021, Sotagliflozin in patients with diabetes and recent worsening heart failure, N Engl J Med sourceExperimental — accuracy not yet measured
The Eligibility section (p. 3) requires a diagnosis of type 2 diabetes, supporting that this trial did not enroll people with type 1 diabetes. The Safety End Points section (p. 9) mentions diabetic ketoacidosis but directs readers to a supplementary table for its rates; our copy does not report those rates or establish an exclusion for recent diabetic ketoacidosis. This trial alone also cannot establish the claim about the other outcomes trials. (LLM, conf=0.85)
- Could not verifycites [298] Musso, 2020, Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: a meta-analysis and meta-regression, PLoS Med sourceExperimental — accuracy not yet measured
The Methods (Study selection; page unavailable) and Results (DKA; page unavailable) concern trials of SGLT2 inhibitors in people with type 1 diabetes, not the cardiovascular or heart-failure outcomes trials named in the claim. Searches for those trials’ ketoacidosis rates and exclusions, including recent DKA, found no passage addressing them in our copy. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“After 1 year of treatment, the mean change in the score was 13.7 points with semaglutide and 6.4 points with placebo, and the mean body weight was reduced by 9.8% in the group assigned to semaglutide compared with 3.4% with placebo.”
What the sources say
- Supportedcites [306] Kosiborod, 2024, Semaglutide in patients with obesity-related heart failure and type 2 diabetes, N Engl J Med source
The Abstract passage in our copy identifies STEP-HFpEF DM and reports the KCCQ-CSS changes as 13.7 points with semaglutide and 6.4 with placebo. It also reports mean body-weight changes of −9.8% and −3.4%, respectively, after 52 weeks. (LLM, conf=0.94)
plaindirectn = 616- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The selective nonsteroidal MRA finerenone was examined in the Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) trial of people with symptomatic HFpEF (ejection fraction ≥40%) and was found to reduce the risk of”
What the sources say
- Supportedcites [303] Solomon, 2024, Finerenone in heart failure with mildly reduced or preserved ejection fraction, N Engl J Med source
The Trial Participants section specifies symptomatic heart failure and ejection fraction of at least 40%. The Methods/Results passage reports fewer total worsening heart failure events or cardiovascular deaths with finerenone than placebo, with a rate ratio of 0.84 (95% CI, 0.74–0.95), corresponding to a 16% lower rate. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Supported
In the paper
“The primary outcome of nonfatal stroke, nonfatal MI, treatment or hospitalization for heart failure, or death from cardiovascular causes was reduced by 21% in the intensive treatment group (hazard ratio [HR] 0.79, 95% CI 0.69–0.90)”
What the sources say
- Not checked — no full text of the sourcecites [42] Bi, 2025, Intensive blood-pressure control in patients with type 2 diabetes, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The primary outcome, a composite of MI, revascularization, hospitalization for heart failure, stroke, or cardiovascular death, was significantly reduced by 12% in the intensive therapy group (HR 0.88, 95% CI 0.78–0.99) irrespective of the diagnosis of diabetes at baseline.”
What the sources say
- Not checked — no full text of the sourcecites [43] Liu, 2024, Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Participants with diabetes comprised nearly 20% of the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial, which noted decreased cardiovascular events with treatment of hypertension to a systolic blood pressure goal of <130 mmHg (41).”
What the sources say
- Not checked — no full text of the sourcecites [41] Zhang, 2021, Trial of intensive blood-pressure control in older patients with hypertension, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Comorbid conditions including overweight and obesity and hypertension often precede the development of HFpEF and have been implicated in the pathophysiology of HFpEF (14).”
What the sources say
- Not checked — no full text of the sourcecites [14] Redfield, 2023, Heart failure with preserved ejection fraction: a review, JAMA source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Adverse event rates were similar in the two groups, although symptomatic hypotension and hyperkalemia were more frequent in the intensive therapy group (42).”
What the sources say
- Not checked — no full text of the sourcecites [42] Bi, 2025, Intensive blood-pressure control in patients with type 2 diabetes, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The cardiovascular event rates, defined as fatal or nonfatal MI, fatal and nonfatal strokes, and all other cardiovascular events, were not significantly different between diastolic blood pressure goals (≤90 mmHg, ≤85 mmHg, and ≤80 mmHg), although the lowest incidence of cardiovascular events occurred with an achieved diastolic blood pressure of 82 mmHg.”
What the sources say
- Not checked — no full text of the sourcecites [47] Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet source
plainn = 18,790- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“β-Blockers are indicated in the setting of prior MI, active angina, or HFrEF but have not been shown to reduce mortality as blood pressure–lowering agents in the absence of these conditions (36,70,71).”
What the sources say
- Not checked — no full text of the sourcecites [36] Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet source
- Not checked — no full text of the sourcecites [70] Carlberg, 2004, Atenolol in hypertension: is it a wise choice?, Lancet source
- Not checked — no full text of the sourcecites [71] Murphy, 2020, Heart failure with reduced ejection fraction: a review, JAMA source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The cardiovascular benefit in this large meta-analysis did not depend on baseline LDL cholesterol levels and was linearly related to the LDL cholesterol reduction without a low threshold beyond which there was no benefit observed (101).”
What the sources say
- Not checked — no full text of the sourcecites [101] Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet source
plaincorrelationaln = 18,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L] and especially >1,000 mg/dL [>11.3 mmol/L]) may warrant pharmacologic therapy (fibric acid derivatives and/or fish oil) and reduction in fat intake to reduce the risk of acute pancreatitis (145).”
What the sources say
- Not checked — no full text of the sourcecites [145] Pedersen, 2016, Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis, JAMA Intern Med source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“While considering these alternative treatment plans, the addition of nonstatin treatment plans to maximum tolerated statin therapy should be considered, as these are frequently associated with improved medication-taking behavior and achievement of LDL cholesterol goals (127).”
What the sources say
- Not checked — no full text of the sourcecites [127] Cheeley, 2022, NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient, J Clin Lipidol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The PCSK9 monoclonal antibodies alirocumab and evolocumab both have been shown to be effective for LDL cholesterol reduction and fewer skeletal muscle–related adverse effects when studied in populations considered statin intolerant.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (154) and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (155).”
What the sources say
- Not checked — no full text of the sourcecites [155] Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A meta-analysis of 13 randomized statin trials with 91,140 participants showed an odds ratio of 1.09 for a new diagnosis of diabetes, so that (on average) treatment of 255 individuals with statins for 4 years resulted in one additional case of diabetes while simultaneously preventing 5.4 vascular events among those 255 individuals (157).”
What the sources say
- Not checked — no full text of the sourcecites [157] Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The risk of rhabdomyolysis is more common with higher doses of statins and renal insufficiency and appears to be higher when statins are combined with gemfibrozil (compared with fenofibrate) (152).”
What the sources say
- Not checked — no full text of the sourcecites [152] Jones, 2005, Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin, Am J Cardiol source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Thus, aspirin appears to have a modest effect on ischemic vascular events, with the absolute decrease in events depending on the underlying ASCVD risk.”
What the sources say
- Not checked — no full text of the sourcecites [176] Pignone, 2006, Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis, Ann Intern Med source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, for adults with ASCVD risk >1% per year, the number of ASCVD events prevented will be similar to the number of episodes of bleeding induced, although these complications do not have equal effects on long-term health (176).”
What the sources say
- Not checked — no full text of the sourcecites [176] Pignone, 2006, Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis, Ann Intern Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The net clinical benefit (ischemic benefit vs. bleeding risk) was improved with ticagrelor therapy in the large prespecified subgroup of individuals with history of percutaneous coronary intervention, while no net benefit was seen in individuals without prior percutaneous coronary intervention (190).”
What the sources say
- Not checked — no full text of the sourcecites [190] Bhatt, 2019, Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the U.S., the most common low-dose tablet is 81 mg, and it appears that 75–162 mg/day is optimal.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“There is little evidence to support any specific dose, but using the lowest possible dose may help to reduce side effects (184).”
What the sources say
- Not checked — no full text of the sourcecites [184] Campbell, 2007, Aspirin dose for the prevention of cardiovascular disease: a systematic review, JAMA source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The major cardiovascular outcome trial of dapagliflozin (10 mg daily) did not show a reduction in the coprimary outcome of MI, stroke, or cardiovascular death but did show a significantly lower rate of the coprimary composite outcome of hospitalization for heart failure or cardiovascular death, which was driven by its effect on hospitalization for heart failure.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Notably, classical symptoms of claudication are uncommon, and almost half of people with newly diagnosed PAD were asymptomatic (223).”
What the sources say
- Not checked — no full text of the sourcecites [223] Hirsch, 2001, Peripheral arterial disease detection, awareness, and treatment in primary care, JAMA source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Although the number needed to invite for screening to prevent one death was close to 170, vascular screening was associated with increased pharmacologic therapy (antiplatelet, lipid-lowering, and antihypertensive therapy), reduced in-hospital time for PAD and coronary artery disease, and reduced mortality (232).”
What the sources say
- Not checked — no full text of the sourcecites [232] Lindholt, 2017, Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial, Lancet source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Treatment with carvedilol reduced mortality by 23%, and there was a 14% risk reduction for heart failure hospitalization.”
What the sources say
- Not checked — no full text of the sourcecites [279] Dargie, 2001, Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The efficacy and safety of SGLT2 inhibitors for reduction of cardiovascular and kidney events in people with type 1 diabetes is being investigated and is not currently recommended due to a significant increase of diabetic ketoacidosis and euglycemic ketoacidosis (266).”
What the sources say
- Not matchedcites [266] National Library of Medicine. ClincalTrial.gov . Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease (SUGARNSALT) (NCT06217302). Bethesda, MD, National Library of Medicine. Accessed 19 August 2025. Available from https://clinicaltrials.gov/study/NCT06217302
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In summary, the numerous large randomized controlled trials report statistically significant reductions in cardiovascular events for three of the FDA-approved SGLT2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) and four FDA-approved GLP-1 RAs (liraglutide, albiglutide [although that agent was removed from the market for business reasons], semaglutide [subcutaneous and oral”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Most evidence supporting interventions to reduce cardiovascular risk in diabetes comes from trials of people with type 2 diabetes.
“Notably, most of the evidence supporting interventions to reduce cardiovascular risk in diabetes comes from trials of people with type 2 diabetes.”
The paper relies on this without support.
No randomized trials have been specifically designed to assess the impact of cardiovascular risk reduction strategies in people with type 1 diabetes.
“No randomized trials have been specifically designed to assess the impact of cardiovascular risk reduction strategies in people with type 1 diabetes.”
The paper relies on this without support.
SGLT inhibitors and/or GLP-1 RAs have demonstrated cardiovascular and kidney benefit in people with type 2 diabetes.
“major benefit observed across the spectrum of CVD, heart failure, and kidney outcomes in people with type 2 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors or glucagon-like peptide 1 receptor agonists (GLP-1 RAs).”
The paper relies on this without support.
Hypertension is a major risk factor for ASCVD, heart failure, and microvascular complications.
“Hypertension is a major risk factor for ASCVD, heart failure, and microvascular complications.”
The paper relies on this without support.
During pregnancy, treatment with ACE inhibitors, ARBs, direct renin inhibitors, MRAs, and neprilysin inhibitors are contraindicated, as they may cause fetal damage.
“During pregnancy, treatment with ACE inhibitors, ARBs, direct renin inhibitors, mineralocorticoid receptor antagonists (MRAs), and neprilysin inhibitors are contraindicated, as they may cause fetal damage.”
The paper relies on this without support.
There is an absence of high-quality data available to guide blood pressure goals in people with type 1 diabetes.
“Notably, there is an absence of high-quality data available to guide blood pressure goals in people with type 1 diabetes, but a similar blood pressure goal of <130/80 mmHg is recommended in people with type 1 diabetes.”
The paper relies on this without support.
People with type 2 diabetes have an increased prevalence of lipid abnormalities, contributing to their high risk of ASCVD.
“People with type 2 diabetes have an increased prevalence of lipid abnormalities, contributing to their high risk of ASCVD.”
The paper relies on this without support.
Glycemic management may beneficially modify plasma lipid levels, particularly in people with very high triglycerides and poor glycemic management.
“Glycemic management may also beneficially modify plasma lipid levels, particularly in people with very high triglycerides and poor glycemic management.”
The paper relies on this without support.
High-intensity statin therapy achieves an approximately ≥50% reduction in LDL cholesterol, and moderate-intensity statin therapy achieves 30–49% reductions in LDL cholesterol.
“High-intensity statin therapy will achieve an approximately ≥50% reduction in LDL cholesterol, and moderate-intensity statin plans achieve 30–49% reductions in LDL cholesterol.”
The paper relies on this without support.
Individuals <40 years of age have lower risk of developing a cardiovascular event over a 10-year period but high lifetime risk of developing CVD and experiencing an MI, stroke, or cardiovascular death.
“Individuals <40 years of age have lower risk of developing a cardiovascular event over a 10-year period; however, their lifetime risk of developing CVD and experiencing an MI, stroke, or cardiovascular death is high.”
The paper relies on this without support.
Low levels of HDL cholesterol, often associated with elevated triglyceride levels, are the most prevalent pattern of dyslipidemia in people with type 2 diabetes.
“Low levels of HDL cholesterol, often associated with elevated triglyceride levels, are the most prevalent pattern of dyslipidemia in people with type 2 diabetes.”
The paper relies on this without support.
No cardiovascular outcome trials have been performed to assess whether PCSK9 inhibitor therapy reduces ASCVD event rates in individuals at low or moderate risk for ASCVD (primary prevention).
“No cardiovascular outcome trials have been performed to assess whether PCSK9 inhibitor therapy reduces ASCVD event rates in individuals at low or moderate risk for ASCVD (primary prevention).”
The paper relies on this without support.
Trials evaluating efficacy and safety of lipid-lowering medications exclude pregnant individuals and require individuals of childbearing potential to use contraception.
“The trials evaluating the efficacy and safety of lipid-lowering medications exclude individuals who are pregnant and require individuals of childbearing potential to use contraception (some requiring two forms).”
The paper relies on this without support.
There is limited information regarding the use of lipid-lowering therapies (other than bile acid sequestrants) during pregnancy.
“There is limited information regarding the use of lipid-lowering therapies (other than bile acid sequestrants) during pregnancy.”
The paper relies on this without support.
Less evidence is available for individuals aged >75 years, as few older people with diabetes have been enrolled in primary prevention trials.
“Less evidence is available for individuals aged >75 years, as few older people with diabetes have been enrolled in primary prevention trials.”
The paper relies on this without support.
No randomized controlled trials specifically assessing cardiovascular outcomes of adding ezetimibe or PCSK9 inhibitors to statin therapy in primary prevention exist.
“While there are no randomized controlled trials specifically assessing cardiovascular outcomes of adding ezetimibe or PCSK9 inhibitors to statin therapy in primary prevention, a portion of the participants without established CVD were included in some studies, which also included participants with established CVD.”
The paper relies on this without support.
Combination therapy with a statin and fibrate is associated with an increased risk for abnormal transaminase levels, myositis, and rhabdomyolysis.
“Combination therapy (statin and fibrate) is associated with an increased risk for abnormal transaminase levels, myositis, and rhabdomyolysis.”
The paper relies on this without support.
Natriuretic peptide levels may be decreased in people with obesity, which impairs sensitivity of testing.
“Conversely, natriuretic peptide levels may be decreased in people with obesity, which impairs sensitivity of testing.”
The paper relies on this without support.
Aspirin use in individuals aged <21 years is generally contraindicated due to the associated risk of Reye syndrome.
“Aspirin use in individuals aged <21 years is generally contraindicated due to the associated risk of Reye syndrome.”
The paper relies on this without support.
Many individuals with PAD remain asymptomatic either because they limit physical activity to avoid claudication symptoms or because a comorbid condition prevents them from reaching a threshold of activity to provoke symptoms.
“Many individuals with PAD remain asymptomatic either because they limit physical activity to avoid claudication symptoms or because a comorbid condition prevents them from reaching a threshold of activity to provoke symptoms.”
The paper relies on this without support.
In the U.S., the most common low-dose aspirin tablet is 81 mg.
“In the U.S., the most common low-dose tablet is 81 mg, and it appears that 75–162 mg/day is optimal.”
The paper relies on this without support.
Current guideline-directed medical therapy for a history of MI and symptomatic stage C and D heart failure in people with diabetes is similar to that for people without diabetes.
“In general, current guideline-directed medical therapy for a history of MI and symptomatic stage C and D heart failure in people with diabetes is similar to that for people without diabetes.”
The paper relies on this without support.
The occurrence of other risk factors or situations is generally needed to precipitate the onset of diabetic ketoacidosis or euglycemic ketoacidosis with SGLT2 inhibitors.
“generally the occurrence of other risk factors or situations is needed to precipitate the onset of diabetic ketoacidosis or euglycemic ketoacidosis, including, but not limited to, a systemic illness, insulin pump malfunctions, significant reduction in insulin doses, and prolonged periods of fasting or carbohydrate restriction.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Abstract
“The STEP trial assigned 8,511 individuals aged 60–80 years with hypertension to a systolic blood pressure goal of 110 to <130 mmHg (intensive treatment) or 130 to <150 mmHg (40).”
§ Abstract
“Participants with diabetes comprised nearly 20% of the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial, which noted decreased cardiovascular events with treatment of hypertension to a systolic blood pressure goal of <130 mmHg (41).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Abstract
“CKD (estimated glomerular filtration rate [eGFR] 30 to <60 mL/min/1.72 m2)”
§ Abstract
“estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2”
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Research works printed but not linked: 3
- Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 140, e596
- Jones, 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, e114
- Stogios, 2020, Advancing digital health interventions as a clinically applied science for blood pressure reduction: a systematic review and meta-analysis, Can J Cardiol, 36, 764
Cited by
Sorted by citations
Marston, N., Bohula, E. A., Bhatia, A. K., Ferrari, G. M. D., Leiter, L., Nicolau, J. C., Park, J., Murphy, S. A., Walsh, E., Liu, L., et al. (2026) · JAMA · doi:10.1001/jama.2026.3277 · Cited by 28
Chan, J. C. N., Deerochanawong, C., Khunti, K., Hassanein, M. M., & Mohan, V. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113173 · Cited by 6
Lan, N. S. R., Fegan, P. G., & Jenkins, A. J. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109268 · Cited by 2
Shoji, T., & Wanner, C. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22048 · Cited by 2
Tiwari, D., Loh, W. J., & Aw, T. C. (2026) · LabMed · doi:10.3390/labmed3020010 · Cited by 2
“The 2026 ADA update continues to prioritize glucose-independent benefits of specific pharmacologic classes, alongside practical guidance for weight management for CKM disorders [33,34].”
Influential
Metadata
- Authors
- American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., Das, S. R., Dixon, D. L., Echouffo-Tcheugui, J. B., Everett, B. M., Garg, R., Laffel, L. M., Lal, R., Matfin, G., Pandya, N., Pekas, E. J., Peters, A. L., Pilla, S. J., Romeo, G. R., Rosas, S. E., Segal, A. R., Szmuilowicz, E. D., & ElSayed, N. A.
- ORCID
- Bajaj, Mandeep
- McCoy, Rozalina G.
- Balapattabi, Kirthikaa
- Bannuru, Raveendhara R.
- Bellini, Natalie J.
- Bennett, Allison K.
- Beverly, Elizabeth A.
- Briggs Early, Kathaleen
- ChallaSivaKanaka, Sathyavathi
- Das, Sandeep R.
- Dixon, Dave L.
- Echouffo-Tcheugui, Justin B.
- Everett, Brendan M.
- Garg, Rajesh
- Laffel, Lori M.
- Lal, Rayhan
- Pandya, Naushira
- Pekas, Elizabeth J.
- Peters, Anne L.
- Pilla, Scott J.
- Romeo, Giulio R.
- Rosas, Sylvia E.
- Segal, Alissa R.
- Szmuilowicz, Emily D.
- ElSayed, Nuha A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2025-12-08
- Volume
- 49
- Issue
- Supplement_1
- Pages
- S216-S245
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC12690187
- OpenAlex
- W4417121408
- Cited by
- 107
- References
- 298
- Citations by year
- 2026: 107
- FWCI
- 63.21
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cardiovascular disease, cardiovascular risk management, diabetes mellitus, clinical guidelines, quality of care, treatment goals, level of evidence
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Humans, Risk Management, Societies, Medical, United States, Diabetes Complications, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
